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Resumo  
O cancro é uma das patologias mais agressivas e letais, permanecendo um desafio 
para investigadores e médicos, mesmo após décadas de investigação e investimento 
nesta área. A deteção tardia e as limitações das terapias atuais, associadas a quimio-
resistência e efeitos adversos, são os principais problemas. 
O melanoma é um tumor melanocítico altamente imunogénico e com elevada 
predisposição para metastizar. A sua incidência tem vindo a aumentar em todo o mundo 
e as taxas de mortalidade associadas a esta doença são muito elevadas. Deste modo, é 
necessário estabelecer terapias alternativas que superem as atuais limitações do 
tratamento, nomeadamente aumentando o espectro e a eficácia e diminuindo a 
toxicidade dos medicamentos usados atualmente. Uma boa estratégia para evitar a 
resistência tumoral exige moléculas com múltiplos alvos. 
As xantonas são naturalmente obtidas em plantas de grande porte e também em 
microrganismos. Notáveis propriedades farmacêuticas foram descritas para estes 
compostos, principalmente o seu potencial anti-tumoral, que contribuiu para a 
comercialização de suplementos alimentares, para o isolamento e para a síntese de 
numerosos derivados xantónicos. No cancro, o efeito promovido por estes, compromete 
várias vias fisiológicas, interferindo com múltiplas características do cancro, incluindo a 
apoptose, ciclo celular, angiogénese, a inflamação e a vigilância imunitária, tornando-os 
um potencial candidato a fármaco. 
O objetivo principal deste estudo foi avaliar os efeitos de duas xantonas, alfa-
mangostina e 1,2-dihidroxixantona, no crescimento da linha celular humana de melanoma 
A375-C5 e a sua capacidade para modular o micro-ambiente imunológico dependente de 
macrófagos. Foi avaliada a capacidade dos compostos para interagir com os diferentes 
parâmetros imunológicos que podem interferir com o tratamento de tumores, incluindo a 
produção de óxido nítrico e a expressão de citocinas, como a interleucina1 beta e o fator 
de necrose tumoral alfa (características do fenótipo M1 em macrófagos) e a interleucina 
10 e o fator transformador do crescimento beta 1 (características do fenótipo M2). A alfa-
mangostina também foi testada em linfócitos, isto é, na proliferação celular e produção de 
citoquinas. Esta atividade foi previamente descrita para a 1,2-dihidroxixantona. Em todos 
os ensaios, foram usados sistemas celulares in vitro, maioritariamente de origem 
humana. 
As xantonas causaram uma diminuição na produção de óxido nítrico e interferiram 
com a expressão de citocinas por macrófagos e / ou linfócitos estimulados. A alfa-
mangostina inibiu a expressão da interleucina 1 beta e do fator transformador do 
crescimento beta 1, e estimulou o fator de necrose tumoral alfa. A 1,2-dihidroxixantona 
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inibiu a interleucina 1 beta e a interleucina 10, estimulou ainda o fator transformador do 
crescimento beta 1 e o fator de necrose tumoral alfa em macrófagos. A alfa-mangostina 
também interferiu com a proliferação de linfócitos e a expressão da interleucina 10 e do 
fator de necrose tumoral alfa por estas células. 
Quanto ao impacto direto dessa modulação no crescimento de melanoma, os 
compostos apresentam uma melhoria de efeito citotóxico. No entanto, só no tratamento 
com 1,2-dihidroxixantona, esta melhoria pode ser associada com a modulação de 
macrófagos pela xantona, uma vez que o efeito da alfa-mangostina em doses baixas é 
semelhante aos macrófagos não tratados na linha celular em estudo. 
Em conclusão, estes resultados permitiram inferir um impacto potencial da alfa-
mangostina e da 1,2-dihidroxixantona no tratamento do melanoma, devido à sua 
atividade citotóxica e ao sugestivo efeito imunoterapêutico em tumores. 
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Abstract 
Cancer is one of the most aggressive and lethal diseases, remaining a challenge for 
researchers and physicians, in spite of decades of research and investment in this area. 
Later detection and constrains of current therapies, associated with chemoresistance and 
toxic side effects, are the main problems. 
Melanoma is a melanocytic tumor highly immunogenic and with a great predisposition 
to metastasize. Its incidence is increasing worldwide and the mortality rates associated to 
the disease are very high. Therefore, it is imperative to find therapeutic alternatives that 
overcome the actual limitations of the treatment, namely improving the spectrum and 
efficacy of actuation and decrease the toxicity of currently used drugs. A good strategy to 
avoid the tumor resistance needs a drug that targets multiple pathways. 
Xanthones are naturally obtained from higher plants and microorganisms. Remarkable 
pharmacologic proprieties have been described for these compounds, mainly their 
antitumor potential, which contributed to their commercialization as dietary supplement, 
isolation and synthesis of numerous derivatives of xanthones. In cancer, their effect 
comprises several physiologic pathways, interfering with multiple hallmarks of cancer, 
including apoptosis, cell cycle, angiogenesis, inflammation and immune surveillance 
making them a prospective drug candidate.  
The main gold of this study was the evaluation of the effects of two xanthones, alpha-
mangostin and 1,2-dihydroxyxanthone, on A375-C5 melanoma cell growth and their 
capacity to modulate the immune macrophages-dependent microenvironment. The ability 
for the compounds to interact with different immunologic parameters that may interfere 
with tumor treatment were evaluated, including production of nitric oxide and expression 
of cytokines interleukin-1β and tumor necrosis factor-α (characteristics of M1 phenotype) 
and interleukin-10 and transforming growth factor-β1 (characteristic of M2 phenotype). 
alpha-Mangostin was also tested in lymphocytes, namely in cell proliferation and 
cytokines production. This activity was previously described for 1,2-dihydroxyxanthone. In 
all assays, in vitro cellular systems were used, mostly of human origin. 
Xanthones caused a decrease in nitric oxide production and interfere with the 
expression of cytokines by stimulated macrophages and/or lymphocytes. Alpha-mangostin 
suppressed expression of interleukin-1β and transforming growth factor-β1, and 
stimulated tumor necrosis factor-α. 1,2-Dihydroxyxanthone inhibited interleukin-1β and 
interleukin-10, stimulated transforming growth factor-β1 and tumor necrosis factor-α in 
macrophages. Alpha-mangostin also interferes with lymphocytes proliferation and the 
expression of interleukin-10 and tumor necrosis factor-α by these cells. Concerning the 
direct impact of this modulation on melanoma growth, the compounds exhibit an 
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improvement of cytotoxic effect. However, only in 1,2-dihydroxyxanthone treatment, this 
improvement could be associated with modulation of macrophages, since the effect of 
alpha-mangostin at lower doses is similar to non-treated macrophages in the cell line in 
study. 
In conclusion, these finds allowed to infer a prospective impact of alpha-mangostin and 
1,2-dihydroxyxanthone in melanoma treatment, due to their cytotoxic activity and 
suggestive effect in cancer immunotherapy. 
 
  
  
 
 
 
 
   
 
I. General Introduction 
Xanthones, melanoma and immune system  
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Chemistry of xanthones: General considerations 
Xanthones are biologically active tricyclic molecules characterized by a dibenzo-γ-
pyrone nucleus or 9H-xanthen-9-one (Figure 1) (Pinto et al. 2005; Mazimba et al. 2013).  
 
 
  
 
The diversity of xanthone derivatives is possible due to the variation of the nature and 
position of substituents on the A and B rings. According to that, natural xanthones may be 
categorized into: simple oxygenated, glycosylated, prenylated and their derivatives 
(xanthone dimers, xanthonolignoids, and miscellaneous). On the other hand, the synthetic 
xanthones can have simple groups such as hydroxyl, methoxyl, methyl, carboxyl, as well 
as more complex substituents such as epoxide, azole, methylidenebutyrolactone, 
aminoalcohol, sulfamoyl, methylthiocarboxylic acid, and dihydropyridine in their scaffold 
(Pinto et al. 2005). 
Natural xanthones of higher plants mainly occur in two families, Guttiferae and 
Gentianaceae, and can also be found in microorganisms as fungi and lichens (Vieira and 
Kijjoa 2005; Mazimba et al. 2013). The majority of these compounds was obtained from 
Garcinia mangostana Linn, being the most abundant and frequently studied, the α-
mangostin, β-mangostin, γ-mangostin, garcinone E and gartanin (Figure 2) (Shan et al. 
2011). 
Figure 1 Xanthone basic skeleton 
I.  
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Xanthones have shown remarkable biological/pharmacological activities linked with 
their tricyclic scaffold, depending on the nature and/or position of the diverse constituents 
(Mazimba et al. 2013). As xanthones from natural origin are quite limited in type and 
position of the substituents due to the biosynthetic pathways, the syntheses of new 
xanthones can attempt to alter or improve their activity by having different nature and 
positions of the substituents on the nucleus of these compounds (Pedro et al. 2002). 
 
Biological activities of xanthones 
In the last decade, the interest for natural or derivative xanthones has been growing as 
readily confirmed by the increased numbers of scientific reports (Gutierrez-Orozco and 
Failla 2013). These have allowed to find a great variety of  biological/pharmacological 
activities associated with xanthone derivatives including analgesic (Bianco et al. 1989; 
Garrido et al. 2001; Cui et al. 2010), antioxidant (Madan et al. 2002; Jung et al. 2006), 
anti-inflammatory (Lin et al. 1996; Madan et al. 2002; Teixeira et al. 2005; Chen et al. 
2008), antitumor (Pinto et al. 2005; Pedraza-Chaverri et al. 2008; Shan et al. 2011; 
Gutierrez-Orozco and Failla 2013), antiallergic (Pfister et al. 1972; Nakatani et al. 2002), 
antimicrobial (Pinto et al. 2005; Pedraza-Chaverri et al. 2008), neuroprotective (Li and 
Ohizumi 2004; Weecharangsan et al. 2006) and immunomodulatory (Makare et al. 2001; 
Tang et al. 2009). 
In spite of all promising proprieties in the improvement of treatment of a number of 
pathologies as cancer (Pinto et al. 2005; Shan et al. 2011), diabetes (Ichiki et al. 1998; 
Figure 2: Structure of the main xanthones from mangosteen 
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Bumrungpert et al. 2009), cardiac (Jiang et al. 2004; Devi Sampath and Vijayaraghavan 
2007), psychiatric (Chairungsrilerd et al. 1996), autoimmune (Madan et al. 2002; Yusuf-
Makagiansar et al. 2002; Leiro et al. 2004) and neurodegenerative pathologies 
(Weecharangsan et al. 2006; El-Seedi et al. 2010), it is important to note that the majority 
of the compounds were only evaluated in cell lines or animal models. According to that the 
safety and efficacy of these products cannot be completely assure. 
Vadimezan (5,6-dimethylxanthenone-4-acetic acid, DMXAA), a promising anticancer 
xanthone that presented important proprieties as vascular disrupting-agent is an example 
of the need of appropriated clinical trial. This compound was tested until phase II trial 
suggesting potential application in combination with paclitaxel and carboplatin for non-
small-cell lung cancer (McKeage et al. 2009). Although, the phase III revealed a lack of 
utility to human use against this cancer due to a specie-specific role (Baguley and Ching; 
Lara et al. 2011).  
 
Antitumor activity 
Among all physiological activities mediated by xanthone compounds, the antitumor 
capacity seemed to be quite remarkable since they exert their inhibitory effect in a 
significant range of tumors. This activity was demonstrated in vitro and/or in vivo on breast 
(Pedro et al. 2002; Moongkarndi et al. 2004; García-Rivera et al. 2011), colorectal (Gobbi 
et al. 2002; Nakagawa et al. 2007; Watanapokasin et al. 2010), prostate (Johnson et al. 
2012), colon (Chitchumroonchokchai et al. 2013), lung (Kostakis et al. 2002; Suksamrarn 
et al. 2006; Rajendran et al. 2008), glioma (Chao et al. 2011), hepatoma (Ho et al. 2002; 
Zou et al. 2004), leukemia (Kostakis et al. 2002; Seo et al. 2002; Matsumoto et al. 2003; 
Yao et al. 2010) and melanoma (Joseph et al. 1999; Pedro et al. 2002; Wang et al. 2011), 
among others (Pinto et al. 2005; Gutierrez-Orozco and Failla 2013). Analyze analyse  
The chemotherapeutic and chemopreventive potential owing their inhibitory effect on 
every steps in the process of tumorigenesis (initiation, promotion, and progression) and on 
multiple signaling targets (Sun et al. 2002; Liu et al. 2013). Indeed, these compounds are 
able to modulate a considerable number of hallmarks of cancer by induce cell cycle arrest, 
suppression of tumor cell proliferation, induction of apoptosis, differentiation, reduction of 
inflammation, and inhibition of adhesion, invasion, and metastasis (Pinto et al. 2005; Akao 
et al. 2008; Pedraza-Chaverri et al. 2008; Shan et al. 2011; Gutierrez-Orozco and Failla 
2013).  
The induction of apoptosis may be possible, among other factors, due activation of 
caspase cascade and disruption of mitochondrial membrane and consequent release of 
cytochrome c (Matsumoto et al. 2004). Antiproliferative effects of xanthones were 
demonstrated as result of cell cycle arrest at G1 and S phases (Matsumoto et al. 2005). 
I.  
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The inhibition of metastatic process is likely associated to inhibition of matrix 
metalloproteinase (MMPs; particularly MMP-2 and MMP-9) and u-PA (urokinase - 
plasminogen activator) expression by JNK1/2 (Jun N-terminal kinase), NF-κB (nuclear 
factor kappa-B) and AP-1 (activator protein 1) activity suppression (Hung et al. 2009).  
Therefore, xanthones could be agents of an emerging antitumor therapy capable of 
alter multiple signaling targets, affect various traits of cancer and consequently prevent 
adaptive resistance (Hanahan and Weinberg 2011; Liu et al. 2013). 
 
Anti-inflammatory activity 
There is a range of evidences from the involvement of inflammatory pathways in 
tumorigenesis (Kundu and Surh 2008). Xanthones have demonstrated both, antitumor 
and anti-inflammatory potential. 
Several xanthone derivatives, mainly the natural ones, attenuated the expression of 
inflammatory mediators as TNF-α (tumor necrosis factor-α) and interleukins 6 (IL-6) in cell 
lines of macrophages and adipocytes and decreased the activation of signaling pathways 
including IL-1, mitogen-activated protein kinase (MEK), Jun N-terminal kinase (JNK), 
extracellular signal-regulated kinase (ERK), signal transducer and activator of 
transcription 1 (STAT-1), NF-κB, AP-1 in these cells (Kumar et al. 2003; Leiro et al. 2004; 
Bumrungpert and Kalpravidh 2010; Liu et al. 2012).  Immunomodulatory effects were also 
observed in murine models (Jang et al. 2012). 
Reduction of inducible NO synthase (iNOS) mRNA was reported for several xanthones 
in murine macrophages cell lines (Garrido et al. 2004; Teixeira et al. 2005; Chen et al. 
2008; Tewtrakul et al. 2009) or murine models (Leiro et al. 2003). Decreased levels of 
cyclooxygenase-2 (COX-2) were also associated with activity of xanthones (Leiro et al. 
2004; Chen et al. 2008; Tewtrakul et al. 2009). 
This represents a small part of all the reported anti-inflammatory effects of xanthones, 
many others could be added to those as demonstrated in some published reviews (Pinto 
et al. 2005; Shan et al. 2011; Gutierrez-Orozco et al. 2013). 
 
Melanoma 
Melanoma is a malignancy of melanocytes or their precursors, the melanoblasts 
(Asnaghi et al. 2012). This is primarily located in the skin, but can also be found in ears, 
gastrointestinal tract, eyes, oral and genital mucosa and leptomeninges (McCourt et al. 
2014). The main risk factor associated to this cancer is the excess of sun exposition as 
repeatedly referred in several prevention campaigns. In spite of this attempt to control 
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emerging cases, its incidence rate is still rising worldwide at highest levels than other 
tumors (Maio 2012; Liu et al. 2014). 
Melanocytic tumors presented a highly predisposition to metastasize, however, when 
early detected frequently means a successful treatment and increasing of survival. 
Contrariwise, metastatic tumors represent poor prognostic with high associated mortality 
(Korn et al. 2008; Gast et al. 2011).  
Melanoma tumorigenesis requires a multistep process, however, a great variety of 
evidences referred the crucial involvement of immune system in tumor progression 
(Hussein 2004). The character highly immunogenic of melanocytic tumors and the 
influence of host immune response and microenvironment inflammatory cells in cancer 
growth were verified (Hussein 2004; Dranoff 2009; Chen et al. 2011). Indeed, primary 
melanomas undergo spontaneous regression much more frequently than any other 
cancer that may be a sign of immunosurveillance or, by other way, it may be due 
melanoma are easier to visualize (Printz 2001; Kalialis et al. 2009). Nevertheless, other 
evidences corroborate the involvement of immune system, namely the relatively amount 
of tumor-infiltrating lymphocytes in melanoma microenvironment compared with other 
cancers and associated with favorable prognostic (Maio 2012; Kushnir and Merimsky 
2013) and the appearance of autoimmune condition as vitiligo in melanoma patients or 
patients treated with immunotherapy which normally means a better disease outcome (Le 
Gal et al. 2001; Phan et al. 2001; Boasberg et al. 2006). 
In more advanced stages, this cancer became capable to avoid immunosurveillance 
(Reiman et al. 2007; Speeckaert et al. 2011) and its progression and metastatic potential 
may be supported by immune cells present in tumor microenvironment, as the tumor-
associated macrophages (TAMs) since they are the most abundant leucocytes in 
melanoma and represent a poor prognostic (Brocker et al. 1988; Bernengo et al. 2000; 
Makitie et al. 2001; Varney et al. 2005; Porta et al. 2007; Solinas et al. 2009; Mantovani 
and Sica 2010; Qian and Pollard 2010). 
 
Immune System 
Immune system is a complex network of cells, tissues and organ that plays an 
important role in defense against multiple microorganisms and toxins and it is essential to 
organism homeostasis by respond not only to exogenous, but also to endogenous signals 
(Matzinger 2002). As is known, this system could be divided in two components, the 
innate and adaptive immunity.  
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Innate immunity is the immediate response to a “danger” and comprises a variety of 
cells, including dendritic cells (DC), macrophages, neutrophils and natural killer (NK) cells 
(Vesely et al. 2011; Lakshmi Narendra et al. 2013). 
Adaptive immunity is antigen specific due to somatic rearrangement on genes that 
codify each receptor of lymphocytes, i.e. the T cell receptor (TCR) for T lymphocytes and 
immunoglobin for B lymphocytes. Beyond T and B lymphocytes, adaptive immune system 
comprises humoral mediators including cytokines and antibodies (Vesely et al. 2011; 
Lakshmi Narendra et al. 2013). 
 
Macrophages 
Macrophages are essential cells of innate immune system that play an important role in 
host defense and tissue homeostasis maintenance (Gordon and Martinez 2010). They 
derived from circulating monocytes originates from monocytic precursors of bone marrow. 
Monocytes are attracted to target tissues where differentiate into mature macrophages 
(Murray and Wynn 2011; Davies et al. 2013). 
Macrophages are heterogeneous cells able to polarize in different subtypes among the 
classic phenotype (M1) and the alternatives (M2-like), according to the received stimuli 
which influence their immune response (Figure 3) (Mantovani et al. 2002; Martinez et al. 
2009). The M1 phenotype is triggered by Th1 (T-helper 1 lymphocyte) cytokine interferon-
γ (IFN-γ), bacteria constituents (like LPS) or Toll-like receptors (TLRs) agonists. Once 
activated, M1 macrophages produce pro-inflammatory cytokines such as TNF-α, IL-1β, IL-
6 and IL-23, great quantities of MHC (major histocompatibility complex) class I and II 
(essential for antigen presentation), nitric oxide (NO) and pro-inflammatory chemokines. 
They promote the recruitment of Th1 cells, CD8+ CTL (cytotoxic T cells) and NK cells 
leading to an inflammatory response and antitumor immunity. (Mantovani et al. 2002; 
Mantovani et al. 2004; Fairweather and Cihakova 2009; Hao et al. 2012; Sica and 
Mantovani 2012). 
Conversely, M2 macrophages are activated by Th2 cytokines, including IL-4 and IL-13, 
or only by IL-10. They express high levels of IL-10 and TGF-β and immunosuppressive 
chemokines. M2-like phenotype favors the recruitment and development of Treg 
(regulatory T cells) and Th2, leading to a response that supports tumor growth through 
immunosuppression (Coffelt et al. 2009; Martinez et al. 2009; Siveen and Kuttan 2009; 
Hao et al. 2012; Sica and Mantovani 2012). However, is difficult to establish a linear effect 
of M1 and M2 macrophages in immune system. 
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Figure 3: Polarization of macrophages and corresponding functions. Legend: GC indicate glucocorticoid; IC, 
immune complex; IL-1ra, IL-1 receptor antagonist; LPS, lipopolysaccharide; MR, mannose receptor; SR, 
scavenger receptor - adapted from (Chanmee et al. 2014). 
 
T lymphocytes 
T lymphocytes or T cells derived from lymphoid precursors and develop in the thymus. 
They express specific receptors (TCRs) capable to recognize peptides (antigens) 
presented by APCs (antigen-presenting cells, namely dendritic cells) and direct or 
indirectly by macrophages. T cells may be classified into cytotoxic T lymphocytes (CD8+ 
CTL) when recognize peptides presented by MHC class I or T helper cells (CD4+ 
Th) if they detect antigens from MHC class II (Fauci et al. 2009; Lakshmi Narendra 
et al. 2013). 
Naïve CD8+ T could proliferate and differentiate into effectors (or CTLs) and 
memory CD8+ T cells after appropriate activation signals. CTLs produce cytokines 
(as INF-γ) and effector molecules (perforin and granzyme-B) with cytotoxic effect 
on the targets including infected or cancer cells (Lakshmi Narendra et al. 2013). 
CD4+ T cells are a much heterogeneous group: they can be subdivided into 
Th1 (expressing IFN-γ, TNF-α and IL-2), Th2 (expressing IL-4-, IL-5, IL-10 and IL-
13), Th17 (producing IL-17), T follicular helper cells (TFH), and Treg depending of 
stimuli (Munk and Emoto 1995; Wilson et al. 2009; Zhou et al. 2009).  
Th1 collaborate with CTLs and regulate the duration and magnitude of pro-
inflammatory or anti-tumor CTLs actions (Romagnani et al. 1997). 
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In contrast with Th1, Th2 induce T cells anergy, suppressing CTLs response 
and promoting protumor humoral immune response (Parker 1993; Lakshmi 
Narendra et al. 2013).  
Regulatory T cells (Treg) may be separated into natutal (nTreg) and inducible 
(iTreg or Tr1). Natural Treg mediate immunossupressive via cell contact-
dependent mechanisms (as granzyme-B/perforin or Fas/Fas ligand pathways) and 
maintain the immune tolerance (Raimondi et al. 2007). Tr1 is induced by 
microenvironment signals as antigens, IL-2, TGF-β and IL-10, and exert an 
immunosuppressive effect by produce anti-inflammatory cytokines (Roncarolo et 
al. 2001; Roncarolo et al. 2006; Bergmann et al. 2007). 
 
Nitric Oxide 
Nitric oxide (NO) is an endogenous gas produced by nitric oxide synthases (NOS) by 
L-arginine. It is an important cellular signaling molecule involved either in physiologic 
(including maintenance of blood pressure, neuronal mediation and inflammation) or 
pathological process (as vascular shock, stroke, diabetes, arthritis, chronic inflammation 
and cancer) (Gross and Wolin 1995; Kuo and Schroeder 1995; Hou et al. 1999). In 
mammalians, the main isoforms of the NOS enzyme are the endothelial (eNOS or NOS3), 
neuronal (nNOS or NOS1) and inducible (iNOS or NOS2). NOS1 and NOS3 are 
expressed constitutively in neuronal and endothelial cells, respectively, depending on 
calcium concentration. NOS2 is an inducible calcium-independent isoform expressed after 
immunologic stimuli in, theoretically, all cells (Moncada et al. 1991; Gross and Wolin 1995; 
U. 2012). 
In cancer, NO effect seemed to be biphasic. Below a critical concentration of NO, it 
causes DNA mutations (Wink et al. 1998), inhibits apoptosis (Choi et al. 2002), promotes 
angiogenesis (Ziche and Morbidelli 2000), limits immune response against cancer (Wink 
et al. 1991) and promotes metastasis (Lala and Orucevic 1998). When it exceeds the 
critical concentration, NO induce apoptosis and suppress the growth of the tumor 
(Choudhari et al. 2013).  
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Cytokines 
Cytokines are small proteins essentials to the interaction and communications between 
cells. They interact in a complex pathway in an autocrine, paracrine or endocrine manner 
with synergic or antagonist outcome, since a single cytokine may act on several different 
cell types (Figure 4) (Zhang and An 2007).  
 
 
Monokines, interleukins and lymphokines are different types of cytokines. They are 
produced by a variety of immune or endothelial cells; however helper T cells (Th) and 
macrophages are the predominant producers (Zhang and An 2007).  
In spite of their importance in several physiologic processes, they have been also 
associated to pathologic condition. Tumor cell and cells from tumor microenvironment, for 
example, showed aberrant production of cytokine (Kurzrock 2001; Jin et al. 2004). 
Cytokines are commonly divided in pro-inflammatory and anti-inflammatory.  
Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are pro-inflammatory 
chemokines frequently associated either to immunosurveillance against cancer, or tumor 
progression. Anti-inflammatory cytokines, as transforming growth factor- β (TGF-β) and IL-
10, also show complex effects on tumor development. 
IL-1β is only produced after stimulation by inflammatory signals. It has been associated 
with all steps of malignancy (carcinogenesis, progression, invasion and metastasis) (Apte 
and Voronov 2008) and was related with metastasis promotion in melanoma models in 
vivo (Giavazzi et al. 1990; Meyer et al. 2011). In contrast, this interleukin is highly 
produced by M1 macrophages, important promoters of immune response against 
Figure 4 Cytokine network in immune system – adapted from (Zhang and An 2007) 
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malignant cells, which means that IL-1β may facilitate immunosurveilance, limiting tumor 
growth and progression (Fairweather and Cihakova 2009). 
TNF-α can induce different signaling pathways, including a pro-apoptotic and an anti-
apoptotic, among others (Chen and Goeddel 2002). According to that, its effect is a 
double-edge sword in carcinogenesis. Higher concentration of this cytokine can induce an 
antitumor response (Wiemann and Starnes 1994; Herman et al. 2013). In agreement, 
inhibitors of TNF appear to increase the risk of skin cancer, including melanoma (Mariette 
et al. 2011; Kouklakis et al. 2013). In contrast, low levels of it can induce tumor 
phenotypes by promote reactive oxygen/nitrogen species generation, causing DNA 
damage and promoting tumorigenesis (Woo et al. 2000; Hussain et al. 2003; Balkwill 
2006). 
 TGF-β presents immunosuppressive and anti-inflammatory properties, involved in 
multiple physiologic pathways including embryogenesis, proliferation and differentiation 
(Santibanez et al. 2011). Their role in cancer is controversial. In early stages of cancer it 
promotes cell cycle arrest and apoptosis, acting as tumor suppressor. In later stages TGF-
β stimulated the invasion and metastasis, inducing epithelial-mesenchymal transition 
(Akhurst and Derynck 2001; Morrison et al. 2013). In melanoma, TGF-β isoforms (TGF-
β1/2/3) are highly expressed and increase in parallel with tumor progression (Krasagakis 
et al. 1998; Javelaud et al. 2008). According to that, this cytokine is commonly produced 
by M2-like macrophages leads to a Th2 response, i.e., promotes an immunosuppressive 
microenvironment that allows the tumor immune escape (Coffelt et al. 2009; Martinez et 
al. 2009; Siveen and Kuttan 2009; Hao et al. 2012; Sica and Mantovani 2012).  
IL-10 is produced by almost all immune cells (as T and B cell, macrophages and 
monocytes, mast cells, granulocytes, dendritic cells and keratinocytes) (Sabat et al. 2010; 
Costa et al. 2013) and can also be produced by tumor cells (Gastl et al. 1993). In cancer, 
its effect is, once again, paradoxical. IL-10 can exert antitumor activity in glioma, 
melanomas, breast and ovarian carcinomas (Lin and Karin 2007) may be through 
downregulation of MHC I and consequent induction of NK-mediated tumor cell lysis 
(Kundu and Fulton 1997). However, IL-10 can allow the immune escape by tumor and 
reduce antigen presentation, cell maturation, differentiation and apoptosis (Zeng et al. 
2010; Hamidullah et al. 2012). 
 
Tumor immunology 
In case of malignant transformation, characteristic mutations of cancer produce tumor-
associated antigens (TAAs) that may allow immune activation and tumor control (Spurrell 
and Lockley 2014).  
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However, the persistence of tumors implies immune scape by several mechanisms. 
Same tumors lose essential functions to immune activation as the failure in expression of 
MHC molecules (responsible to antigen presentation and consequent T cell activation). 
Others express immunosuppressive cytokines or create physical barriers to avoid 
immunosurveillance (Spurrell and Lockley 2014). 
From all inflammatory cells, macrophages or tumor-associated macrophages (TAMs) 
seemed to have the most important functions in malignancies (Chen et al. 2011). In fact, 
during tumor development macrophages have mostly M1 phenotypes and promote an 
immune response against cancer, however, in later-stages of tumor, TAMs frequently 
exhibit M2-like phenotypes (Sica and Mantovani 2012). M2-like TAMs represent a worst 
prognostic, since they favor tumor growth and survival through induction of angiogenesis 
and suppression of cytotoxic activity of T lymphocytes (Tsutsui et al. 2005; Zijlmans et al. 
2006; Mantovani and Sica 2010). 
Figure 5 represents the interaction between innate and adaptive immunity and 
consequent effects on tumors. It reinforces the controversial effect of immune system, i.e. 
a set of immune cell (as M1 macrophages, NK, CTLs and Th1 cells) and specifics 
cytokines detect and control tumor progression, while other cells (like M2-macrophages, 
Th2 and Tregs) and derived cytokines, frequently present at later stages of cancer, 
contribute to their progression and immune scape. 
Nevertheless, the role of immune system in cancer is not so linear because, this is 
influenced by the tumor microenvironment. Some immune cells are heterogeneous and 
present high plasticity, altering their phenotypes in response to cancer which explains the 
frequent inconsistent effects verified. In fact, the protumor or antitumor effects of each 
immune cell depend on cytokines signaling present in tumor microenvironment and it will 
determine their mode of differentiation (Lakshmi Narendra et al. 2013). 
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Figure 5: Schematic presentation of the role of immune system in cancer. Legend: APC indicates antigen -
presenting cell; CTL, cytotoxic T lymphocyte or CD8+ T cell; NK, natural killer cell; Th, T helper cell; Treg, 
regulatory T cell and TAA, tumor-associated antigens - adapted from (Lakshmi Narendra et al. 2013).  
APC 
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Xanthones as potential agents in melanoma treatment  
Melanoma mortality rates are a devastating reality and a concern for investigators and 
physicians. The main reason for the poor outcome is the few treatment options. Standard 
treatments, chemo and radiotherapy, are inefficient in many cases (Flaherty 2010); 
alternative therapies as BRAF inhibitors are only useful for patients with the mutation and  
either for a relative short time (Solit and Rosen 2011); ipilimumab, an immunomodulating 
antibody that target CTLA4 on activated T cells and inhibit regulatory T cells, exhibit 
severe toxicity (Hodi et al. 2010; Graziani et al. 2012). 
Clearly, the achievement of an efficient therapeutic agent in melanoma patients is 
desirable that to act in multiple targets in different biochemical pathways to avoid tumor 
escape mechanisms (Smalley et al. 2006). 
Taking into account all biologic activities that have been associated with xanthone 
derivatives, lead some of them to be interesting candidates for melanoma treatment.  
In fact, a great variety of xanthones showed significant antitumor activity against 
human and murine melanoma cell lines and also in vivo. Antitumor activity of xanthones 
from mangosteen were reported against human melanoma SK-MEL-28 (Wang et al. 2011; 
Wang et al. 2012a; Wang et al. 2012b; Wang et al. 2013) and, most recently, in highly 
metastatic murine melanoma B16-F10 and in A375 human melanoma (Beninati et al. 
2014). Similar effects have been reported for other natural xanthones (Azebaze et al. 
2007) and synthetic xanthones (Valenti et al. 1993; Joseph et al. 1999; Chen et al. 2000; 
Pedro et al. 2002; Sousa et al. 2002). In spite of and as far as we know, there are no 
studies in α-MG effect on melanoma cells growth by SRB assay.   
Natural xanthones has been shown remarkable activities in the improvement of human 
health, particularly in cancer. However, the biochemical pathways restrict the possible 
structures of xanthones and do not allow taking the full potential of these compounds. In 
order to overtake this limitation, some investigations try to find the relationship between 
structure and biological activities. Pedro et al established some of these important 
relationships associated to different xanthone compounds and concluded that their effects 
depend on the nature of substituents, the position where these are placed in the xanthonic 
nucleus and, sometimes, depends on the cell type. The knowledge of these interactions is 
an important step for achieve a xanthonic derivative more specific and efficient for 
particular diseases and decrease the potential side effects of natural xanthones (view 
chapter V: paper 1). 
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Importance of immunomodulation in melanoma treatment 
As previously referred, several evidences highlighted the importance of 
immunomodulation of tumor microenvironment in the control of melanoma. 
The reported immunologic effects of xanthones are not restricted to few pathways; 
these compounds influence either innate or adaptive immune system. Their particular 
effect on NO and cytokines production by macrophages was already attested. Natural 
xanthones inhibited NO production and TNF-α secretion by murine macrophages cell lines 
(Chen et al. 2008; Tewtrakul et al. 2009; Boonnak et al. 2014). In U397 human 
macrophages-like cell lines, natural compounds decreased the expression of inflammatory 
genes (as TNF-α and IL-6) and inhibited the Th1 and Th2 differentiation (Bumrungpert et 
al. 2010; Liu et al. 2012). Contrariwise, Gutierrez-Orozco et al. described an over 
expression of TNF-α by primary monocyte-derived macrophages treated with alpha-
mangostin (Gutierrez-Orozco et al. 2013). In vivo results confirm the anti-inflammatory 
activities in several rat models (Shankaranarayan et al. 1979; Jang et al. 2012). 
Nevertheless, the experiments in humans, even being scarce, showed inconsistencies 
and some pro-inflammatory cytokines levels, as IL-1β and complement components, were 
increased, while other markers of inflammation, as C-reactive protein level, were reduced 
(Tang et al. 2009; Udani et al. 2009). NO inhibition in murine macrophages was also 
described for synthetic xanthones (Teixeira et al. 2005). 
In spite of the verified interaction of immune system in melanoma treatment and the 
potential of xanthones as antitumor and immunomodulatory agents, any research was 
based on the direct effect of xanthone in the immune microenvironment of tumor. 
Macrophages play an essential role in malignancies (Chen et al. 2011) and they are 
fundamental agents for activation of adaptive immune system (Heidenreich 1999). 
According to that, study of macrophage involvement on immune microenvironment of 
tumor appeared to be an important start, in particular to analyze of the xanthones 
outcome in malignancies. 
Immune system is a well regulated network, T lymphocytes are able to modulate the 
polarization of macrophages and, in turn, macrophages control the response of T 
lymphocytes (Hao et al. 2012; Sica and Mantovani 2012). According to that reciprocal 
interaction, lymphocytes may interfere with macrophages response in cancer and the 
effect of xanthones on these immune cells functions is also important for antitumor 
studies. 
Effect of xanthones from mangosteen in cytokines release by lymphocytes from 
peripheral blood was described only once. Kasemwattanaroj et al showed that alpha-
mangostin did not induce the production of pro-inflammatory cytokines (TNF-α and IL-1β) 
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or cytokines of adaptive immunity (IL-2) in lymphocytes (Kasemwattanaroj et al. 2013). A 
research in healthy humans, using 59 mL per day for 30 days of a xanthone-rich 
mangosteen supplement, increased the ratio of T helper to cytotoxic cells (Tang et al. 
2009). However, in tumor murine models exposed to gambogic acid, a natural prenylated 
xanthone, induced an activation of T lymphocytes and a consequent induction of tumor 
apoptosis (Gu et al. 2008). 
Other natural xanthones showed divergent function in lymphocytes proliferation: 
xanthones from Calophyllum teysmannii var. inuphylloide inhibit their proliferation 
(Gonzalez et al. 1999), while xanthones from Gentiana barbata activated their proliferation 
and induced the formation of specific cytolytic T-killers (Nikolaeva et al. 2004). Some 
synthetic xanthones also showed anti-proliferative potential in lymphocytes isolated from 
peripheral blood (Pedro et al. 2002; Sousa et al. 2002). 
The controversial data concerning the immunomodulatory activity of xanthones needs 
to be clarified in order to understand the potential of these compounds in cancer 
treatment, namely in melanoma due to it immunogenic character.  
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The main goal of this project was the evaluation of two xanthone derivatives, alpha-
mangostin and 1,2-dihydroxyxanthone, in modulation of macrophages activity as well as 
the result in cytotoxic effect on melanoma cell line, since macrophages are key cells in 
tumor immune microenvironment. 
 
Therefore, the following were required: 
 Evaluate the antitumor activity of referred compounds in the growth of A375-C5 
human melanoma cell line by SRB assay; 
 Measure the effects of xanthone-induced macrophage-conditioned medium on the 
proliferation of the human melanoma cell line A375-C5 by SRB assay; 
 Compare the effects of the compounds and the macrophages-conditioned medium 
on the growth of A375-C5 cell line;  
 Evaluate the interference of the compounds with NO production by LPS-stimulated 
RAW 264.7 murine macrophages, using Griess reagent; 
 Access the impact of compounds on the cytokine expression profile by PMA-
differentiated THP-1 cells and their polarization into M1 (IL-1 and TNF-α) or M2 (IL-
10 and TGF-β1) phenotype, by an ELISA kit; 
 Determine the antiproliferative effect of compounds on PHA stimulated human 
mononuclear cells by MTT assay and their interference with cytokines expression, 
using an ELISA kit. 
 Define THP-1, RAW 264.7 and human mononuclear cells viability after treatment 
with the compounds by MTT-assay. 
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Chemicals and reagents 
Reagents used in cell culture, including RPMI-1640, DMEM medium, and fetal bovine 
serum (FBS) were purchased from Gibco® Invitrogen Co. (Barcelona, Spain), 2-
mercaptoethanol for synthesis was obtained from Merck (Whitehouse Station, NJ, USA), 
Glutamine cell culture grade and Dimethyl sulfoxide (DMSO) from Applichem (Darmstadt, 
Germany). N.N-Dimetilformamida (DMF) was acquiring from Spectramol Science 
Incorporated. 
Reagents used in SRB assay as Trichloroacetic acid (TCA) and Acetic acid glacial 99-
100% were purchased from Prolabo (Oeiras, Portugal) and CHEM-LAB (Zedelgem, 
Belgium), respectively. 
IL-1β, IL-10, TNF-α and TGF-β1 ELISA Ready-Set-Go Kits were acquired from 
eBioscience (San Diego, CA, USA). 
All other chemicals of analytical grade used in the experiments and unless otherwise 
indicated were purchased from Sigma-Aldrich® (St. Louis, MO, USA). 
 
Xanthones 
Alpha-mangostin (α-MG) was obtained from Sigma-Aldrich® (ref.M3824) and 1,2-
dihydroxyxanthone (1,2-DHX) was synthetized in Laboratory of Organic and Pharmaceutic 
Chemistry (Faculty of Pharmacy, University of Porto) and in CEQUIMED (Centro de 
Química Medicinal; University of Porto) as previously described (Gales et al. 2001) 
 Stock solution of compounds kept at -20ºC in DMSO. Just prior each assay, stock 
solutions were diluted in appropriate complete medium to the maximum concentration 
desired to test and 1:2 dilutions were serially prepared. 
 
Cell lines 
A375-C5 human malignant melanoma cell line and RAW 264.7 mouse macrophage 
cell line are part of CEQUIMED cell culture collection. THP-1 human monocyte cell line 
was a courtesy of Rui Appelberg. 
A375-C5 was routinely maintained in 25 cm2 flasks containing RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 1 µL mL-1 Gentamycin at 37ºC in a 
humidified incubator with 5% CO2. For the THP-1 cell line the culture medium just 
described was also supplemented with 0.05 mM 2-mercaptoethanol. RAW 264.7 cell line 
was maintained in 75 cm2 flasks containing DMEM medium with the same percentage of 
FBS and gentamycin, and at the same conditions. 
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Cell lines were sub-cultured every 2 or 3 days by trypsinization (A375-C5), replacement 
of the medium (THP-1) or scraping (RAW 264.7) and used for each experiment when the 
cells were in exponential growth. 
Human mononuclear cells were isolated from peripheral blood of healthy volunteers by 
Histopaque-1077 density centrifugation. All volunteers assign an informed consent. 
Mononuclear cells were ressuspended in RPMI medium supplemented with 10% FBS and 
1 µL mL-1 gentamycin. 
 
Cell growth assay 
The effect of α-MG on the growth of A375-C5 cell line was determined by 
sulphorrodamine B (SRB) method adopted by the National Cancer Institute (NCI, USA) 
(Monks et al. 1991) and as already described by our group (Pedro et al. 2002; Gupta et al. 
2008). 
A375-C5 cell line was plated into 96-well flat-bottom tissue culture plates at a 
concentration of 7,5 x 104 cells mL-1 in complete culture medium and incubated for 24 h in 
a 5% CO2 humidified incubator (HERA cell 150, Heraeus) at 37ºC. Once adherent, cells of 
one of the plates were immediately fixed for a no-growth control (designed Tzero plate) to 
determine the basal protein amount. Simultaneously, cell of test plates were treated with 
serial dilutions of xanthones and incubated for another 48h. 
Cells were then fixed with 50 µL of 50% TCA solution and incubated for 1h at 4ºC. 
Cells were washed five times with deionized water and allowed to dry. Fixed cells were 
exposed to 50 µL SRB dye (0,4% w/v in 1% acetic acid) for 30 minutes at room 
temperature. The unbound dye was removed by wash five times with 1% (v/v) acetic acid 
manually. Once completely dried, 100 µL of 10 mM Tris base solution was added and left 
for 30 minutes at room temperature to solubilize SRB. The absorbance was measured in 
an ELISA reader (Stat Fax 3200, Awareness Technology). Doxorubicin (1:10 dilutions) 
was used as positive control. 
Growth inhibition of 50% (GI50) was calculated by comparing, after 48 h, the 
absorbance of the xanthone-treated cells with the absorbance of Tzero plate. Lower 
absorbance after 48 h of treatment indicate occurrence of cell death instead of growth 
arrest (Monks et al. 1991). 
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Antitumor effect of conditioned macrophages culture medium 
THP-1 human monocyte cell line is a simple, suitable and reliable model to study 
monocytes and macrophages functions or responses and the possible effects from 
external stimuli as new drugs. Differentiation of this cell line in mature THP-1 monocyte-
derived macrophages can be achieve using phorbol-12-myristate-13-acetate (PMA), the 
most efficient differentiation agent in this case (Chanput et al. 2012; Chanput et al. 2014). 
THP-1 cell line was plated at 1 X 105 cells mL-1 in 96-wells flat-bottom plates and 
differentiated into THP-1 macrophages by adding 50 µL of 10 ng mL-1 PMA for 72h in a 
humidified incubator at 37ºC and 5% CO2 (He et al. 2012). Once differentiated, cells were 
washed twice with complete medium and they were incubated for another 24h in culture 
medium to obtain the resting stages of macrophages (Chanput et al. 2012; Chanput et al. 
2014). Then, they were stimulated by 100 µL of a solution of 1 µg mL-1 LPS, 
simultaneously treated with the xanthone in test and incubated for 24h at 37ºC in a 5% 
CO2 humidified incubator (He et al. 2012). Plates were centrifuged to deposit the 
compounds and half of the volume of each well was added to A375-C5 adherent cells, 
previously plated as described in section “cell growth assay”. After a 48h incubation, SRB 
assay was performed, absorbance was measured and cell-growth inhibition determinate 
as just described (Pedro et al. 2002; Gupta et al. 2008). 
 
NO production assay 
The effect of the different compounds in nitric oxide (NO) production by RAW 264.7 
was determined by the Griess reaction as previous described by our group (Teixeira et al. 
2005). RAW 264.7 (1 X 106 cells mL-1) were platted on 96-well flat-bottom plates and 
allowed to adhere for 2h. Supernatants were removed and replaced by 100 µL of fresh 
medium containing 1.5 µg mL-1 LPS in order to induce iNOS synthesis by macrophages. 
The cell were also treated with 100 µL of each xanthone concentration (1:2 dilution) and 
incubated for 24h at 37ºC in a 5% CO2 humidified incubator. Then, 100 µL of supernatants 
were transferred to a new 96-well flat-bottom plates, 100 µL of Griess reagent (some 
quantities of a solution of 1% w/v sulphanilamide in 5% v/v phosphoric acid and a solution 
of 0.1% w/v naphtylethylenediamide in deionized water) was added and it was incubated 
for 10 min at room temperature (Green et al. 1982). Nitrite production was quantified by 
spectrophotometry at 550nm in an ELISA reader. N-nitro-L-arginine methyl ester (L-
NAME) (inhibitor of iNOS activity) and Dexamethasone (inhibitor of iNOS expression) 
were used as positive controls. Inhibition of 50% NO production was measured by 
comparing percentage of NO in treated cells and in non-treated cells.  
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Compounds were also added 6h or 14h after LPS stimulation and significant 
differences detected in NO production between the different moments when xanthones 
were added, works to infer if compounds act in iNOS expression and/or activity. 
 
NO scavenging assay 
To discard NO scavenging effect by xanthones, nitrite was chemically generated, as 
previously described (Teixeira et al. 2005). 50 µL of sodium nitoprusside (5 mM) in PBS 
was added to xanthone dilution and incubated for 150 min at 25ºC. Griess reagent was 
added and nitrite accumulation was quantified. Sodium nitoprusside in PBS (100% 
production) and in ethanol/PBS (9:1; 0% production) were used as controls. 
Scavenging activity, determined in terms of percentage of nitrite formation, was present 
when the percentage of nitrite formed in the presence of the sample was less than 70% of 
the sodium nitroprusside control. 
 
Human mononuclear cells MTT-proliferation assay 
Human mononuclear cells (50 µl of a concentration of 2-3 X 106 cell mL-1) were plated 
in 96-well flat-bottom plates, treated with 50 µL of serial dilutions of α-MG and stimulated 
with 50 µL of PHA (Phytohaemagglutinin; used as a mitogen to trigger T-lymphocyte cell 
division) (10 µg mL-1) and incubated for 96h at 37ºC in a 5% CO2 humidified incubator. 
After incubation, 25 µL of 1 mg mL-1 MTT solution (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) was added to cells. After 4h, the formazan product was 
solubilized overnight with a sodium lauryl sulfate/N,N-dimethylformamide (SDS/DMF) 
solution and absorbance measured at 550 nm (Pedro et al. 2002; Cerqueira et al. 2003; 
Teixeira et al. 2005). Cyclosporin A was used as positive control. Lymphocyte toxicity, 
determined in terms of the percentage of viable cells, was present when the viability of the 
treated cells, compared with that of the non-treated control cells, was less than 70%. 
 
Cytokine quantification 
Culture supernatants of THP-1 differentiated, stimulated and treated cells, as 
previously described in section “Antitumor effect of conditioned macrophages culture 
medium”, were storage at - 20ºC until cytokine analyses.  
Levels of interleukin-1β (IL-1β), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) 
and transforming growth Factor-β1 (TGF-β1) in culture supernatants were quantified by 
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ELISA, using ELISA Ready-SET-Go kit (affymetrix, ebioscience) according to 
manufacturers’ instructions. 
The same cytokines were also evaluated in supernatants of human mononuclear cells 
treated with xanthones for 48h (Lou et al. 2013; Wang et al. 2013), incubation with PHA 
stimulus and three concentrations of α-MG. 
Interference of both compounds or α-MG in cytokines expression by THP-1 and 
lymphocytes, respectively, was accessed comparing treated with non-treated cells.  
 
MTT-viability assay 
Viability assays were performed as described elsewhere by our group (Cerqueira et al. 
2003; Teixeira et al. 2005). 
For lymphocytes, MTT-viability assay was performed after 24h of cells treatment with 
xanthones. For all the other cells, viability assay was executed at the end of the 
experiments to determine the effect of the compound on the cell line. 
Briefly, to cells supernatants, 25 µL of MTT solution was added followed by 4 h 
incubation at 37ºC in a 5% CO2 humidified incubator. After incubation, 50 µL of SDS/DMF 
solution was added and absorbance measured at 550 nm (Pedro et al. 2002; Cerqueira et 
al. 2003; Teixeira et al. 2005). 
Cell toxicity was considered when the viability of the exposed cells was less than 70%.  
 
Statistical analysis  
Except otherwise stated, results are the mean ± SEM of at least three independent 
experiments, performed in duplicate. 
Statistical analysis was performed with SPSS for Windows (version 20.0). Statistical 
significance between two mean was calculated by Mann-Whitney Test and it is considered 
for p values less than 0.05. 
 
Ethics 
Ethics approved was obtained by the Ethic Comity of University Fernando Pessoa. 
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Abstract 
Extracts and derived products of the fruit of the mangosteen tree (Garcinia 
mangostana Linn) are among the top-selling dietary supplements due to a great 
variety of proclaimed pharmacological/biological activities, namely anti-inflammatory, 
antioxidant, anticancer, among others. This fruit (mangosteen) comprises a huge 
variety of compounds, being xanthones the main secondary metabolites and the major 
responsible for the mangosteen declared beneficial characteristics. The knowledge 
about effects of xanthones from mangosteen at cellular and molecular level has been 
increasing and, despite all health improvement indications, have many controversial 
outcomes. The present review focus on potential adverse effects that can be 
anticipated by continuous and/or excessive use of these products. In fact, xanthones 
from mangosteen can interfere with important physiologic functions as immunity, cell 
cycle progression, detoxification and response to serotonin, and may change the 
metabolism of several drugs by altering the activity of drug-metabolizing enzymes. 
Finally, the discussion reinforces the importance of ample studies to assure the safety 
and efficacy of mangosteen derived products for human consumption. 
 
Graphical abstract 
 
 
Key words: Adverse effects; Dietary supplements; Garcinia mangostana Linn; 
Mangosteen; Xanthones; 
 
 
 
V.  
 
42 
 
Abbreviations 
AP-1 – activator protein 1 
CAT – catalase 
cdc2 – cell division cycle protein 2 homolog 
CDK4 – cyclin-dependent kinases 4 
CHEK2 – checkpoint kinase 2 
COX – cyclooxygenase 
CPK – creatine phosphokinase 
CYP – cytochrome P450; 
eNOS – endothelial nitric oxide synthases 
GOT – glutamate oxaloacetate transaminase 
GPT – glutamate pyruvate transaminase 
GPx – glutathione peroxidase 
GSH – glutathione  
GST – glutathione-S-transferase 
IL – interleukins; 
iNOS – inducible nitric oxide synthases 
LDH – lactate dehydrogenase 
LPS – lipopolysaccharides 
MAPKs – mitogen-activated protein kinases 
MCP-1 – monocyte chemoattractant protein-1 
MDM2 – murine doble minute 2 
NF-κB – nuclear factor kappa B 
NO – nitric oxide 
p21
cip1
 – cyclin-dependent kinase inhibitor 1 
p27 – cyclin-dependent kinase inhibitor 
p53 – tumor protein p53 
SOD – superoxide dismutase 
STAT-1 – signal transducer and activator of transcription 1 
TLR-2 – Toll-like receptor-2 
TNF-α – tumour necrosis factor α 
 
1. Introduction 
The use of plants, parts of plants and isolated secondary metabolites for the 
prevention and treatment of various illnesses has been time long-established. 
Garcinia mangostana Linn is a tropical tree that belongs to the family Clusiaceae, 
genus Garcinia has been cultivated for centuries in Southeast Asia and different parts, 
mostly fruit hull, bark and roots, have been used in folk medicine to treat a great 
variety of conditions like infections, wounds, inflammations, dysenteries, among others 
(Obolskiy et al. 2009; Gutierrez-Orozco and Failla 2013) and is not an exception in 
this area. Its fruit, mangosteen, comprises a huge variety of compounds including 
xanthones, flavonoids, triterpenoids, benzophenones, terpenes, anthocyanins, 
tannins, phenols as well as several vitamins (Kosem et al. 2007; Chin and Kinghorn 
2008). In spite of that, xanthones are the most representative secondary metabolites 
of G. mangostana with associated medicinal properties (Chin and Kinghorn 2008; 
Obolskiy et al. 2009). 
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The interest in mangosteen, especially in xanthone derivatives may be illustrated 
by a few important reviews (Pinto et al. 2005; Obolskiy et al. 2009; Shan et al. 2011; 
Gutierrez-Orozco and Failla 2013). A great variety of biological/pharmacological 
properties, as antioxidant (Jung et al. 2006), antitumor (Matsumoto et al. 2003; 
Moongkarndi et al. 2004; Suksamrarn et al. 2006; Nakagawa et al. 2007; Akao et al. 
2008; Watanapokasin et al. 2010; Chao et al. 2011; Krajarng et al. 2011; Wang et al. 
2011; Yoo et al. 2011; Johnson et al. 2012; Chitchumroonchokchai et al. 2013; Leão 
et al. 2013; Wang et al. 2013), immunomodulatory (Tang et al. 2009), cardioprotective 
(Shankaranarayan et al. 1979; Devi Sampath and Vijayaraghavan 2007), 
neuroprotective (Weecharangsan et al. 2006), antiallergic (Nakatani et al. 2002a), 
antimicrobial  (Chen et al. 1996; Suksamrarn et al. 2003; Sakagami et al. 2005; 
Kaomongkolgit et al. 2009) analgesic (Cui et al. 2010) and anti-inflammatory 
(Nakatani et al. 2002b; Chen et al. 2008) have been described.  
The remarkable proclaimed advantages of this plant called the attention of some 
industries that soon started to commercialize a large number of food supplements, 
beverages and others food products containing mangosteen and occasionally others 
juices, advertising for their multiples benefits for human health (Garrity et al. 2004). 
Although herbal medicinal products have been generally considered as relatively 
low risk by the public, potential damage for health can occurs. Very often attention is 
not given to the fact that toxicity also can be associated with natural products, by 
themselves or by contamination, adulteration, plant misidentification, and interactions 
with other herbal products or drugs (Marcason 2006; Jordan et al. 2010; Ibrahim et al.) 
leading to an increased toxicity or loss of therapeutic efficacy (Colalto 2010). 
During last decades increased reports on adverse effects regulatory/monitoring 
agencies in many countries have given alerts for these kind of issues (Shi and Klotz 
2012; Sahoo and Manchikanti 2013), leading to increased attention by the scientific 
community involved in the areas of use of medicinal plants (Foti and Wahlstrom 
2008). 
The present review emerged from research concerning cellular and molecular 
mechanisms modulated by xanthones from mangosteen and focuses on potential 
adverse effects of those xanthones on human physiological pathways. We considered 
this approach is critical because the intake of such products has been increasing even 
without any clinical trials that attest their safety or efficacy to human use.  
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2. Xanthones from mangosteen  
Before discussing the interference of xanthones from mangosteen in the human 
body that could lead to damages, it is important to understand some chemical 
characteristics of these metabolites.  
Xanthones are a class of heterocyclic compounds characterized by a dibenzo-γ-
pyrone nucleus (Pedro et al. 2002; Pinto et al. 2005; Pinto and Castanheiro 2009; 
Mazimba et al. 2013). They are composed by a unique chemical scaffold, the tricyclic 
aromatic system (C6–C3–C6) named xanthene-9-one (Figure 6) (Pinto et al. 2005; 
Teixeira et al. 2005; Obolskiy et al. 2009; Pinto and Castanheiro 2009). 
 
 
Figure 6 Xanthone basic skeleton 
 
Natural xanthones can be categorized, depending on the nature of the substituents, 
into simple oxygenated, glycosylated, prenylated and their derivatives (xanthone 
dimers, xanthonolignoids and miscellaneous) (Pinto et al. 2005; Pinto and 
Castanheiro 2009). 
The main xanthones isolated from the different parts of G. mangostana are α- and 
γ-mangostin, but besides these more than 60 compounds were identified, being the 
most abundant and frequently studied compounds represented in Figure 7 (Chin and 
Kinghorn 2008; Obolskiy et al. 2009; Pinto and Castanheiro 2009; Shan et al. 2011; 
Leão et al. 2013). 
Xanthones of the mangosteen extract are subjected to metabolic clearance 
mediated essentially by multiple cytochrome P450 (CYP) isoforms. CYP1A2 
metabolizes α-mangostin, 9-hydroxycalabaxanthones and 8-deoxygartanin; β-
Mangostin is mainly metabolized by CYP2C9 and while other isoforms, including 
CYP2B6, CYP2C19, CYP3A4 and CYP2D6 get a minor contribution; gartanin is as 
well metabolized by CYP1A2, CYP2B6 and CYP2D6; 3-isomangostin appeared to be 
only metabolized by CYP3A4 (Foti et al. 2009). However, it is important to emphasize 
that the metabolism can vary if it occurs in normal or malignant cells (Gutierrez-
Orozco and Failla 2013). 
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Figure 7 Structure of the main xanthones from mangosteen 
 
3. Potential adverse effects associated with mangosteen  
Taking in consideration that herbal medicines are used as whole plants or plant 
extracts, consisting in combinations of many substances, often with undefined 
composition, the toxicological assessment of these products is not an easy task, even 
though the evaluation of the toxicity of the isolated metabolites can be considered 
routine. If this happens it will be of great interest to correlate the toxicity of these 
compounds with the extract. Although this is not the usual state, there are already 
examples of this type of correlation (Jordan et al. 2010). 
With Garcinia mangostana this kind of study has not been done and one of the 
purposes of this review in the next chapters is to point to the influence of the potential 
toxicity of xanthones from mangosteen, in order to give clues for a future correlation 
with the adverse effects associated with mangosteen extracts. 
 
3.1. Immunomodulation 
Nowadays, many induced alterations on the immune system has been described 
and associated with potential benefits for many illnesses as diabetes, cardiac 
pathologies, cancer and autoimmune diseases (Frangogiannis et al. 2002; Sampath 
and Vijayaragavan 2008; Bumrungpert et al. 2009a; Dougan and Dranoff 2009; 
Hanahan and Weinberg 2011; Singh et al. 2012). However, the immune system 
comprises large and complex pathways with antagonist and/or synergic functions that 
Garcinone E 
Alpha-mangostin Beta-mangostin Gama-mangostin 
Gartanin 
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change according to several conditions as age, gender, stress, environment, among 
others. Consequently, the immune response is hard to predict and interpret (Cohen et 
al. 1991; Lesourd 2002; Beery 2003; Srinivasan et al. 2005). In cancer, for example, 
the innate and adaptive immunity have a dual effect, either preventing tumour 
progression or stimulating their growth, invasiveness and metastatic activity (Dranoff 
2004; Gutkin and Shurin 2014). 
The immune function is essential for organism homeostasis, responding to 
exogenous and endogenous risk signals (Matzinger 2002). Therefore, the 
uncontrolled and unmeasured use of antiphlogistic agents, as mangosteen products, 
may cause severe adverse effects in consumers. 
Exploring recent reports of immunomodulation mediated by these products, we 
noticed that many of these possibly trigger body deregulation.  
The inhibition of pro-inflammatory genes triggered by lipopolysaccharides (LPS) 
was recurrently described and related with xanthones exposure in different cell lines. 
Many authors reported a decrease in gene expression of tumour necrosis factor α 
(TNF-α), several interleukins (IL-1β, IL-6, IL-8), monocyte chemoattractant protein-1 
(MCP-1) and Toll-like receptor-2 (TLR-2) in primary cultures of human adipocytes, 
human U937 macrophages-like cells and murine RAW 264.7 macrophage-like cells 
treated with α- and/or γ-mangostin (Sampath and Vijayaragavan 2008; Bumrungpert 
et al. 2009a; Bumrungpert et al. 2009b; Tewtrakul et al. 2009; Bumrungpert et al. 
2010; Liu et al. 2012; Gutierrez-Orozco et al. 2013). But this effect is not considered to 
be exclusive of macrophages and adipocytes, Gutierrez-Orozco et al. detected similar 
inhibition, mediated by α-mangostin, in human monocyte cell line (THP-1) and 
different cancer cell lines (HepG2, Caco-2 HTB-37, and HT-29) (Gutierrez-Orozco et 
al. 2013). The described alterations on pro-inflammatory genes seems to be 
associated with the interference in some immune pathways, those involving 
conventional mitogen-activated protein kinases (MAPKs), activator protein 1 (AP-1), 
signal transducer and activator of transcription 1 (STAT-1) and nuclear factor kappa B 
(NF-κB) (Sampath and Vijayaragavan 2008; Bumrungpert et al. 2009a; Tewtrakul et 
al. 2009; Liu et al. 2012). These protein cascades are also involved in stress response 
and participate in crosstalk with other signal pathways (Ghosh et al. 1998; Ramana et 
al. 2000; Chang and Karin 2001; Li and Verma 2002; Bonizzi and Karin 2004; Wada 
and Penninger 2004) which means that the effect of xanthones from mangosteen, 
namely α- and/or γ-mangostin, will probably not be confined to immune system 
modulation. 
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Additional restriction on immunity cells action seems to occur at basophils and mast 
cells level. Xanthonic compounds (α-, β- and/or γ-mangostin) and extracts of 
mangosteen reduce degranulation of these cells preventing histamine release 
possibly by interfering with downstream signals (Nakatani et al. 2002a; Itoh et al. 
2008). Moreover, the histaminergic receptors are blocked by α and γ-mangostin 
(Chairungsrilerd et al. 1996). As consequence of this blockage, these compounds 
deregulate the interaction histamine-receptors, a binding implicated in some 
pathological functions including cancer and intestinal ischemia promotion (Kusche et 
al. 1980; Raithel et al. 1998), along with several vital functions, as neurotransmission, 
immunomodulation, haematopoiesis, wound healing and day-night rhythm (Maintz and 
Novak 2007). According to that, a careful medical follow-up is needed to prevent 
possible complications. 
Anti-inflammatory activity of mangosteen extracts and α- and/or γ-mangostin have 
been still linked with enzymatic alterations, namely through inhibition of the mRNA 
expression and/or activity of cyclooxygenases 1 and 2 (COX-1 and COX-2) and/ or 
inducible nitric oxide synthases (iNOS) (Nakatani et al. 2002b; Nakatani et al. 2004; 
Chen et al. 2008; Tewtrakul et al. 2009). COX-1 and COX-2 are involved in 
physiologic processes as well as pathophysiologic events. COX-1 is traditionally 
associated with homeostasis functions, including gastric cytoprotection and 
haemostasis. COX-2 is connected to inflammation and tumourigenesis. In spite of this, 
complementary functions between the two enzymes and variations on their actions 
depending of the specific target organs were reported (Masferrer et al. 1994; Dubois 
et al. 1998; Marnett 2009; Rouzer and Marnett 2009). Inducible nitric oxide synthases 
(iNOS) is responsive for nitric oxide (NO) production after stimulation by 
immunological stimuli, being an intermediary of inflammatory response, however the 
excess or insufficiency of nitric oxide production can cause equally cell damage 
(Gross and Wolin 1995). In cancer, NO seems to have dual effects: multiple reports 
has associated NO with cancer progression  while others has defended the 
therapeutic benefits of NO donors in different cell lines and organisms (Wink et al. 
1991; Lala and Orucevic 1998; Wink et al. 1998; Ziche and Morbidelli 2000; Lala and 
Chakraborty 2001; Choi et al. 2002; Mocellin et al. 2007; Coulter et al. 2008; Yasuda 
2008). 
Considering the importance of all these enzymes in biochemical and physiological 
events the role of xanthones contained in mangosteen extracts should be carefully 
evaluated. 
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3.2. Cell Cycle arrest 
 Cell cycle is a sequence of highly regulated events essential for all living beings. In 
multi-cell organisms are necessary several rounds of cell division to create a new 
individual and during their lifetime it is a crucial mechanism for maintaining appropriate 
cellular and tissue condition once cell death and damages are constant (Alberts 
2008).  
Mechanisms of action of some xanthones from mangosteen are frequently 
associated with cell cycle arrest. Since the cell cycle deregulation is a hallmark of 
cancer and one of the earliest processes of oncogenesis (Syljuasen et al. 1999; 
Hanahan and Weinberg 2011), several authors purposed and proved this effect of 
xanthones in different tumor (Matsumoto et al. 2005; Wang et al. 2011; Johnson et al. 
2012; Kurose et al. 2012; Leão et al. 2013). 
Matsumoto et al. related that xanthones induced cell-cycle arrest in a human colon 
cancer cell line. Mangostins α and β up-regulated p27 and down-regulated cyclin A, 
B1, D1 and E1 and cdc2, phospho-cdc2 (tyrosine 15) expression and consequently 
act at G1-phase, blocking the division progression. However, while some authors 
affirm that γ-mangostin acts at S-phase in human colon cancer (Matsumoto et al. 
2005), others indicate a G1-phase arrest in a human melanoma cell line (Wang et al. 
2011). 
Johnson et al. reported that a prostate cancer cell line treated with α-mangostin 
inhibited cyclins/cyclin-dependent kinases 4 (CDK4) binding, an vital protein complex 
to cell cycle progression from G1 to S-phase (Johnson et al. 2012). According to that, 
Kurose et al. described an up-regulation of p21
cip1
 and CHEK2 (regulator factors of 
G1-phase) in breast cancer model after treatment with α-mangostin (Kurose et al. 
2012). 
 The inhibition of p53-MDM2 interaction due to a potential binding between α-
mangostin and MDM2 was also detected by some of our group (Leão et al. 2013). 
Free p53 stops cell division at both G1 and G2 checkpoints (Agarwal et al. 1995). In 
accordance with our finds, further authors have reported enhance of p53 levels after 
colon and blander cancer treatment with α-mangostin and gartanin, respectively 
(Aisha et al. 2012; Liu et al. 2013).  
 In summary, some xanthones from mangosteen are potent inhibitors of cell cycle 
progression by blocking the division at different levels in different cell models, as 
illustrated in Figure 8. 
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Figure 8 Effect of xanthones of mangosteen at different stages of cell cycle regulation. Legend: cdc indicate 
cell division cycle protein; CDK, cyclin-dependent kinases; Chk or CHEK2, checkpoint kinase; G1, gap phase; 
G2, gap phase 2; M, mitosis phase; MDM2, murine doble minute 2; MG, mangosteen xanthones; p21cip1, 
cyclin-dependent kinase inhibitor 1; p27kip1, cyclin-dependent kinase inhibitor; p53, tumor protein p53; S, 
DNA synthesis phase. 
 
 Besides the importance of that effect in cancer treatment, normal cells have to be 
replaced to keep the tissue homeostasis, specially, tissues with constitutive division. 
Labile tissues as hematopoietic cells in the bone marrow and the majority of epithelial 
tissue (e.g., skin, oral cavity, vagina and cervix, salivary glands, pancreas, biliary and 
gastrointestinal tracts, uterus, fallopian tubes and urinary tract) must have a functional 
cell-cycle to replace the lost cells in injuries and aging process (Kumar et al. 2012). 
Hence that, xanthones of mangosteen referred above (mangostins α, β, γ and 
gartanin) as cell cycle arrest agents may interfere with normal cells replacement. 
 
3.3. Antioxidant effect 
Oxidative stress is a natural process implicated in cell damage or death and it has 
been associated with several human pathologies, like cardiac and neurodegenerative 
diseases and cancer (Valko et al. 2007). The prevention of such stress through 
antioxidant products has been extensively study, however the potential benefits or 
risks associated are still ambiguous (Stanner et al. 2004; Bjelakovic et al. 2013). In 
oncologic patients the advantages of antioxidant use are unclear. Some studies 
admitted survival gains or no interference with chemo or radiotherapy, while others 
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suggest a reduction of the therapeutic effect of chemo or radiotherapy in patients 
simultaneous using antioxidant products (D'Andrea 2005; Moss 2007; Lawenda et al. 
2008; Block et al. 2009).  
As referred previously, many xanthones from mangosteen have antioxidant activity 
(Moongkarndi et al. 2004; Jung et al. 2006; Weecharangsan et al. 2006; Devi 
Sampath and Vijayaraghavan 2007; Kosem et al. 2007; Chin et al. 2008). In fact, Devi 
Sampath and Vijayaraghavan 2007 described an attenuation of isoproterenol 
oxidative effect in rats treated with α-mangostin compared with no-treated rats. They 
demonstrated an augment of antioxidant enzymes glutathione-S-transferase (GST), 
glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT), as 
well as a reduction of glutathione (GSH), lipid peroxides and serum enzymes, 
including lactate dehydrogenase (LDH), creatine phosphokinase (CPK), glutamate 
oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) (Devi 
Sampath and Vijayaraghavan 2007). 
In generally, it is known that some drugs, including cancer drug therapies, can be 
affected by xanthones from mangosteen antioxidant potential. These xanthonic 
derivatives have been connected with alterations on metabolizing enzymes 
responsible for the metabolism of several drugs (Foti et al. 2009). The changes that 
can occur in effect of drugs when co-administrated with these compounds will be 
discussed in the following section. 
Considering the referred controversial use of antioxidants, further studies are 
necessary to confirm the safety of the use of that herbal folk medicine. 
 
3.4. Modifications in the metabolism of therapeutic agents 
On living organisms, exogenous compounds are subjected to biochemical 
modifications catalysed by enzymes responsible for detoxification. Alterations in 
activity of these drug-metabolizing enzymes may jeopardize the treatment response, 
namely in efficacy, toxicity or both (Lu 1998; Evans and Relling 2004). Xanthonic 
components of mangosteen were already associated with modulation of enzymes 
involved in phase I and phase II of the metabolism (Devi Sampath and 
Vijayaraghavan 2007; Balunas et al. 2008; Foti et al. 2009). 
The CYP family are phase I enzymes capable to metabolize the majority of drugs 
(Kalra et al. 2009) including natural xanthones, as already was referred. In spite of 
that, mangosteen has been associated with inhibition of enzymatic activity of some 
CYP members. Foti et al. showed that aqueous mangosteen extract extensible 
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reduced the activity of CYP2C8 and CYP2C9 in human liver microsomes; further 
enzymes were also inhibited but to a less extent. These authors proposed that such 
effect is associated with the presence of α-mangostin, β-mangostin, gartanin, 3-
isomangostin and 8-desoxygartanin in the extract (Foti et al. 2009). Balunas et al. also 
described a potent inhibition of CYP19 (aromatase) mediated by methanol and 
chloroform-soluble extracts of G. mangostana in a human placental microsomes and 
by some xanthones (specially γ-mangostin) in a human breast cancer cell line 
(Balunas et al. 2008). 
CYP2C8 and 2C9 metabolize important drugs (as indicated in Table 1) including 
the therapeutic agents ibuprofen (Davies 1998; Garcia-Martin et al. 2004), paclitaxel, 
phenytoin (Burns 1999; Foti et al. 2009) and warfarin (Burns 1999; Rettie and Tai 
2006; Foti et al. 2009), as well as amitriptyline (Ghahramani et al. 1997; Olesen and 
Linnet 1997), cyclophosphamide (Chang et al. 1993; Chang et al. 1997), diazepam 
(Shou et al. 2000) and losartan (Zhou et al. 2009; Mannheimer and Eliasson 2010). 
Therefore, it is predictable that some of these drugs may become less or even 
ineffective when co-administered with mangosteen products and their toxicity can also 
be increased. 
Similarly, the aromatase inhibition mediated by mangosteen might increase the 
adverse effects of drugs like methadone (Nekhayeva et al. 2005) and hormones 
androstanolone and nortestosterone (Silberzahn et al. 1988; Douglas et al. 2005) or 
reduce the treatment response to others such as methadone derivate 
levacetylmethadol (Deshmukh et al. 2004) and the testosterone (Silberzahn et al. 
1988; Rendic 2002; Morale et al. 2008) (Table 1). Additionally to the metabolic 
activity, CYP19 are also responsible for the bioconversion of androgens into 
estrogens (Simpson et al. 1994). Consequently, the potential of aromatase inhibitors, 
like mangosteen (α, γ-mangostin and garcinones D/E), in treatment of many hormone-
responsive tumors as breast cancer cannot be ignored (Azria et al. 2005; 
Brueggemeier 2006; Kendall and Dowsett 2006). 
Beyond the CYP family, the antioxidant effect of α-mangostin by stimulating several 
enzymes including the glutathione S-transferases (GSTs) (Devi Sampath and 
Vijayaraghavan 2007) must be considered. GSTs are phase II enzymes that catalyse 
the conjugation of many endogenous substances and xenobiotics with glutathione 
(GSH) (Uetrecht and Trager 2007; Oakley 2011; Bousova and Skalova 2012). GSH-
conjugation results, normally, in drug activity inhibition due to increase in solubility of 
compounds and consequently the facility of excretion (Barnouin et al. 1998; Peklak-
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Scott et al. 2005). However in some cases, drug conjugation promotes drug activation 
(Morgan et al. 1998; Findlay et al. 2004; Tew 2005). The anticancer drugs, PABA/NO 
and TLK286 are examples of compounds activated after conjugation (Morgan et al. 
1998; Findlay et al. 2004; Tew 2005) (Table 1). Consequently, the co-administration 
with α-mangostin could promote accumulation of the active metabolites and 
increasing the side effects. 
 
Table 1. Potential effects of xanthones derivatives on drugs metabolism.  
Effect on some 
drug-metabolizing 
enzymes 
Drugs 
metabolized by 
the enzymes # 
Therapeutic activity affected References # 
Decrease CYP2C8 
and 
CYP2C9 activity 
Amprenavir Antiretroviral (HIV-1 inhibitor) (Fung et al. 2000) 
Bupropion Antidepressant tetracyclic 
(Preissner et al. 2010; Knox et 
al. 2011) 
Capsaicin Analgesic (natural) (Reilly et al. 2003) 
Cisapride 
Gastrointestinal prokinetic 
agent 
(Desta et al. 2000; Preissner et 
al. 2010) 
Clozapine * Antipsychotic 
(Fang et al. 1998; Rostami-
Hodjegan et al. 2004) 
Cyamemazine Antipsychotic and anxiolytic (Arbus et al. 2007) 
Dapsone * Antibacterial (Winter et al. 2000) 
Dextromethorphan Cough suppressant 
(von Moltke et al. 1998; 
Preissner et al. 2010) 
Diclofenac * 
Analgesic, antipyretic, anti-
inflammatory 
(Mancy et al. 1999) 
Diltiazem * Cardiovascular (Sutton et al. 1997) 
Estradiol Sex hormones (estrogen) 
(Yamazaki et al. 1998; Cheng et 
al. 2001) 
Fluvastatin * Lipid regulating (Scripture and Pieper 2001) 
Ibuprofen * 
Non-Steroidal Anti-
Inflammatory 
(Davies 1998; Garcia-Martin et 
al. 2004) 
Irbesartan * Cardiovascular 
(Hallberg et al. 2002; Preissner 
et al. 2010) 
Ketamine  Anesthetic and analgesic 
(Hijazi and Boulieu 2002; 
Preissner et al. 2010) 
Ketobemidone Analgesic 
(Kristensen et al. 1996; Yasar et 
al. 2005) 
Lansoprazole * Gastro-intestinal (Pearce et al. 1996) 
Methadone 
Analgesic, antipyretic, anti-
inflammatory 
(Rendic 2002; Zhou et al. 2009) 
Omeprazole * Gastro-intestinal 
(Foti et al. 2009; Preissner et al. 
2010) 
Paclitaxel Antineoplastic (Burns 1999; Foti et al. 2009) 
Perphenazine Antipsychotic 
(Olesen and Linnet 2000; 
Rendic 2002; Preissner et al. 
2010) 
Phenytoin * Antiepileptic (Burns 1999; Foti et al. 2009) 
Phenprocoumon Cardiovascular (Ufer et al. 2004) 
Piroxicam * 
Analgesic, antipyretic,  
Non-steroidal anti-
inflammatory 
(Zhao et al. 1992; Perini et al. 
2005; Preissner et al. 2010) 
Progesterone * Sex hormone (Progestagen) 
(Yamazaki and Shimada 1997; 
Preissner et al. 2010) 
Propofol * General anesthetic (Guitton et al. 1998) 
Quinidine * Cardiovascular 
(Nielsen et al. 1999; Preissner 
et al. 2010) 
Rosiglitazone * Antidiabetic 
(Baldwin et al. 1999; Malinowski 
and Bolesta 2000) 
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Selegiline, 
Deprenyl * 
Antidepressant 
(Rendic 2002; Salonen et al. 
2003) 
Seratrodast * Cardiovascular (Kumar et al. 1997) 
Temazepam Anxiolytic, sedative, hypnotic 
(Ono et al. 1996; Yang et al. 
1998; Rendic 2002) 
Terbinafine Antifungal 
(Vickers et al. 1999; Rendic 
2002) 
Thalidomide Antineoplasic (Ando et al. 2002) 
Tolbutamide * Antidiabetic 
(Srivastava et al. 1991; Rendic 
2002) 
Torasemide, 
Torsemide 
Cardiovascular (Diuretic) 
(Rendic 2002; Kerdpin et al. 
2004; Vormfelde et al. 2004) 
Trimethadione, 
Troxidone 
Antiepileptic 
(Kurata et al. 1998; Rendic 
2002; Tanaka et al. 2003) 
Verapamil * Cardiovascular 
(Tracy et al. 1999; Anthony and 
Berg 2002) 
Warfarin* 
Cardiovascular 
(Anticoagulant) 
(Burns 1999; Rettie and Tai 
2006; Foti et al. 2009) 
Zafirlukast * 
Bronchodilators and Anti-
asthma 
(Dekhuijzen and Koopmans 
2002; Preissner et al. 2010) 
Zopiclone Anxiolytic, sedative, hypnotic 
(Becquemont et al. 1999; 
Rendic 2002) 
Acetylsalicylic acid 
Anticoagulants and 
Antithrombotics 
(Preissner et al. 2010; Knox et 
al. 2011) 
Amitriptyline* Antidepressant 
(Ghahramani et al. 1997; 
Olesen and Linnet 1997) 
Cyclophosphamide 
* 
Antineoplastic 
(Chang et al. 1993; Chang et al. 
1997) 
Diazepam * Anxiolytic, sedative, hypnotic (Shou et al. 2000) 
Ifosfamide * Antineoplastic (Chang et al. 1993) 
Lidocain(e) Local anesthetic 
(Narang et al. 1978; Rendic 
2002) 
Losartan * Anti-Hypertensives 
(Zhou et al. 2009; Mannheimer 
and Eliasson 2010) 
Pioglitazone * Antidiabetic 
(Jaakkola et al. 2006; Preissner 
et al. 2010) 
Sulfadiazine * Antibacterial (Cribb et al. 1995; Rendic 2002) 
Testosterone 
Sex hormone (Androgen and 
anabolic) 
(Yamazaki and Shimada 1997; 
Rendic 2002) 
Troglitazone * Antidiabetic 
(Yamazaki et al. 1999b; He et 
al. 2004) 
Zidovudine, 
azidothymidine 
Antiviral 
(Eagling et al. 1994; Rendic 
2002) 
Brompheniramine Antihistaminic 
(Preissner et al. 2010; Knox et 
al. 2011) 
Caffeine Xanthine (CNS stimulant) 
(Preissner et al. 2010; Knox et 
al. 2011) 
Carbinoxamine 
Antihistamine and 
anticholinergic 
(Preissner et al. 2010; Knox et 
al. 2011) 
Leflunomide * Antirheumatic (Rozman 2002) 
Mefenamic acid * 
Analgesic, antipyretic, anti-
inflammatory 
(Preissner et al. 2010; Knox et 
al. 2011) 
Mephenytoin Antiepileptic 
(Relling et al. 1990; Goldstein et 
al. 1994) 
Meloxicam * 
Analgesic, antipyretic, anti-
inflammatory 
(Turck et al. 1996; Chesne et al. 
1998; Preissner et al. 2010) 
Mirtazapine Antidepressant 
(Stormer et al. 2000; Rendic 
2002) 
Nicotine 
Supplementary drugs and 
other substances 
(Yamazaki et al. 1999a; Rendic 
2002) 
Paracetamol, 
acetaminophen 
Analgesic, antipyretic, anti-
inflammatory 
(Raucy et al. 1989; Rendic 
2002) 
Phenazone, 
Antipyrine 
Analgesic, antipyretic,  
non-steroidal anti-
(Engel et al. 1996; Rendic 2002) 
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Information concerning Cytochrome P450s and Glutathione S-transferases metabolism was obtained from 
SuperCYP (Preissner et al. 2010), DrugBank database (Knox et al. 2011) and additional papers; all drugs 
inflammatory 
Rifampicin * Antibacterial 
(Preissner et al. 2010; Knox et 
al. 2011) 
Rofecoxib 
Non-steroidal anti-
inflammatory 
(Preissner et al. 2010; Knox et 
al. 2011) 
Sulfinpyrazon(e) * Antigout (Rendic 2002) 
Theophylline Xanthine (Bronchodilator) 
(Preissner et al. 2010; Knox et 
al. 2011) 
Trimethoprim * Antiepileptic (Rendic 2002) 
Decrease CYP19 
(aromatase) 
activity 
Betamethason(e) * Corticosteroid (Paakki et al. 2000) 
Letrozole * Antineoplastic (Azria et al. 2005) 
Androstanolone Sex hormones (Androgen) (Douglas et al. 2005) 
Methadone 
Analgesic, antipyretic, anti-
inflammatory 
(Nekhayeva et al. 2005) 
Nandrolone, 
nortestosterone 
Sex hormone (Progestagen) (Silberzahn et al. 1988) 
Levacetylmethadol  
(methadone 
derivate) 
Analgesic, antipyretic, anti-
inflammatory 
(Deshmukh et al. 2004) 
Testosterone 
Sex hormone (Androgen and 
anabolic) 
(Silberzahn et al. 1988; Rendic 
2002; Morale et al. 2008) 
Increase GST 
activity 
Adriamycin or 
Doxorubicin 
Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Busulfan Antineoplastic 
(Vassord et al. 2008; Elhasid et 
al. 2010) 
Carboplatin Antineoplastic (Marsh et al. 2009) 
Carmustin or 
BCNU 
Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Chlorambucil Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003; Parker et al. 2008) 
Cisplatin Antineoplastic 
(Hayes and Pulford 1995; 
Peters et al. 2000; Lien et al. 
2002; Hamilton et al. 2003) 
Cyclophosphamide Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Ecteinascidin-743; 
ET-743 or 
Trabectedin 
Antineoplastic (Brandon et al. 2006) 
Ethacrynic acid Diuretic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Etoposide Antineoplastic (Mans et al. 1992) 
Glutathione Supplementary drug (Hayes et al. 2005) 
Melphalan Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Mitozantrone Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Oxaliplatin Antineoplastic (Marsh et al. 2009) 
Thiotepa Antineoplastic 
(Hayes and Pulford 1995; Lien 
et al. 2002; Hamilton et al. 
2003) 
Azathioprine Antineoplastic (Gianluigi Zaza et al. 2010) 
TLK286 Antineoplastic (Morgan et al. 1998; Tew 2005) 
PABA/NO Antineoplastic (Findlay et al. 2004) 
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indicated on the table are approved by FDA; in drugs metabolized by CYP2C8 and 2C9, only those that are 
metabolized by the two enzymes was listed because the effect of xanthones might be more significant. 
LEGEND: CYP: Cytochrome P450; GST: Glutathione S-transferases; * drugs that, besides substrates, are 
also inhibitors and/or inducers of enzyme activity; # references related to drugs metabolized by such enzyme. 
 
3.5. Blocking serotonin receptors 
Serotonin is a ubiquitous molecule that plays multiple physiological roles including 
cardiovascular, gastrointestinal and endocrine functions, as well as development, 
sensory perception, behaviours such as aggression, appetite, sex, sleep, mood, 
cognition, and memory (Aghajanian and Sanders-Bush 2002). The inhibition of 5-HT2A 
serotonin receptors mediated by γ-mangostin (Chairungsrilerd et al. 1996) was 
described in animal models; this effect may disrupt several essential functions to 
human survival. 
Serotonergic receptor blocking agents are current drugs used in nervous system 
disorders (Chairungsrilerd et al. 1996) making mangosteen supplements good 
candidates for intervention at this level. Their use by healthy people however needs to 
be monitored once this neurotransmitter is intervener in a variety of essential 
biological processes. 
 
3.6. Other effects 
Many others unfavourable proprieties have been linked with the use of 
mangosteen-based products. 
Wong, et al described a case of severe lactic acidosis in a woman who took 
mangosteen juice. The authors postulated that this effect was mediated by α-
mangostin causing mitochondrial injuries (Wong and Klemmer 2008). The loss of 
mitochondrial potential has been described in general by many reviews concerning G. 
mangostana (Pinto et al. 2005; Pedraza-Chaverri et al. 2008; Obolskiy et al. 2009; 
Shan et al. 2011; Chitchumroonchokchai et al. 2013; Gutierrez-Orozco and Failla 
2013); even if only a case of lactic acidosis was reported until now, associated with an 
acute respiratory illness, it is necessary to be watchful to understand the possible 
conditions that improve that risk of its use (Wong and Klemmer 2008). 
Several mangosteen products available in market advertise for their antidiabetic 
potential based on scientific reports. In fact, many authors reported a decrease of 
insulin-resistance augment of sensibility to insulin in animal or cell models after 
treatment with xanthones, namely mangiferin and α and γ-mangosteen (Ichiki et al. 
1998; Miura et al. 2001a; Miura et al. 2001b; Bumrungpert et al. 2009a; Bumrungpert 
et al. 2010). Must be taking in account that mangosteen, as other fruits, contains high 
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quantities of sugar and since there are no studies in antidiabetic effect in humans, the 
advantages or either their safety in diabetics cannot be guaranteed. However, 
mangosteen is processing before commercialized and alterations caused by this 
treatment may induced modifications in xanthones composition. Moreover, those 
products contain additional substances, beyond xanthones (Wong and Klemmer 
2008).  
Finally, FDA (Food and Drugs Administration) alert for the presence of tadalafil in 
two specific commercialized products. This is a substance that may interact with 
nitrates found in some prescription drugs (medication frequently used by diabetics and 
patients who have high blood pressure, high cholesterol or heart diseases) and may 
lower blood pressure to dangerous levels (FDA 2012). The referred example leads to 
speculate about a possible addition of non-declared substances in natural products 
once that an approval is not necessary to their commercialization (FDA 2014). 
 
4. Conclusions 
Herbal-based medicines triggered a huge curiosity in past years about their 
advantages leading to an exponential increasing in marketing. 
The potential of Garcinia mangostana as a botanic dietary supplement has been 
encouraged the investigation at several levels and, in this review, we reinforce the fact 
that mangosteen fruit can show prospective benefits in cancer, diabetes, cardiac, 
psychiatric, autoimmune and neurodegenerative pathologies, as well as in some 
physiologic conditions like oxidative stress and inflammation. 
In spite of those promising proprieties, dietary supplements based on natural 
products, like G. mangostana, are not subjected to rigorous safety testing in humans 
and their control is quite limited since is not necessary a FDA’s approbation. 
Additionally, both safety and efficacy of mangosteen cannot be assured only by 
scientific studies made in cell lines or animal models as has been done so far. 
Furthermore, it is necessary taking in account several parameters to make an 
accurate clinical trial because some biochemical events may alter the mangosteen 
effects and the availability of their active metabolites. The most important of these 
parameters are the part of the fruit that would be used, the extraction method, the type 
and amount of active compounds existent in each extract and the presence of other 
components that can be add to the mangosteen products, as different juices 
(blueberry, cranberry, raspberry, grape, cherry, strawberry, pear, apple, etc), green 
tea (Camellia sinensis), Aloe vera, multivitamins or essential minerals. 
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Another point that has received minimal attention is the characterization of the 
absorption, metabolism and elimination of these compounds in human organism. This 
characterization is critical for establishing a possible toxicity rate of chronic ingestion 
of mangosteen and may allow the determination of possible interactions with 
therapeutic agents. It is also important to verify if the doses of some drugs can be 
reduced by using mangosteen concomitantly. The evaluation of these parameters 
may minimize the adverse response to therapy which is extremely important 
especially for treatments with drugs that cause serious side effects (example of 
chemotherapeutic drugs as paclitaxel, letrozole or azathioprine). 
In summary, this review highlights the importance and the value of extensive 
animal studies, long-term epidemiologic studies and more controlled clinical trials in 
human volunteers (Shan et al. 2011; Gutierrez-Orozco and Failla 2013) for 
mangosteen supplements. Certainly, many other food supplements needed similar 
studies; however mangosteen is one of the top-selling, is easily available, consumed 
without medical control and can modulate several biochemical pathways. Correct 
hazard evaluation, along with analysis of related risk factors of its use, are essential to 
the recognition and avoidance of potential adverse effects. Mangosteen seems to 
have an enormous potential in improvement human’s health, however that only can be 
truthfully accomplish when all of its effects will be completely understand, what 
requires a concerted work in several areas like, chemistry, pharmacology, biology and 
clinic in general. 
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Paper 2 (draft): “Alpha-mangostin antitumor activity: cytotoxicity 
and influence on the immune system microenvironment” 
  
Abstract 
Alpha-mangostin is known to interfere with multiple pathways of carcinogenesis. 
Therefore, it has been proposed as prospective cancer drug candidate. In melanoma, 
alpha-mangostin antitumor effect may be increased by the immunomodulation of tumor 
microenvironment, since melanocytic tumors are highly immunogenic.  
The main gold of this study was evaluate alpha-mangostin (i) cytotoxic effect on A375-
C5 melanoma cell line and (ii) it interference with the immune macrophages induced 
microenvironment of the tumor.  
This xanthone showed inhibition of A375-C5 melanoma growth (GI50 = 11.3 ± 0.9 µM). 
Concerning the direct impact of alpha-mangostin on macrophages function, it was 
observed an inhibition of nitric oxide production by RAW 264.7 murine macrophages (IC50 
= 13.8 ± 0.7 µM) and decreased the concentration of IL-1β and TGF-β1 and stimulated 
TNF-α expression by THP-1 human macrophages. In order to complement the described 
effect of α-MG on the immune microenvironment of melanoma, it was also study in 
proliferation and cytokines production by human lymphocytes. Alpha-mangostin strongly 
inhibited PHA-stimulated human mononuclear cells proliferation (IC50 = 9.2 ± 0.3 µM) but 
not interfering for IC50 for IL-1β, TNF-α, IL-10 and TGF-β1.  
In conclusion this study proved that alpha-mangostin interferes with cytokine and NO 
production by activated macrophages leading to the evidence that the xanthone interferes 
with immune microenvironment of the tumor.  
 
Introduction 
Melanoma is a melanocytes’ malignant tumor that metastasizes very early in the 
disease process, causing elevated mortality rates. According to the Oncologic register of 
Portugal (2007), the world incidence of melanoma of the skin is about 4,5 cases for 
100000 habitants (RORENO 2013) and, although it is a relative rare kind of cancer, it 
contributes for about 80% of the deaths caused by cutaneous cancer (Kuphal and 
Bosserhoff 2009; Gast et al. 2011; Raaijmakers et al. 2013). The tumorigenesis of this 
cancer requires a multistep process, in spite of alterations in immune system has a crucial 
involvement, namely the immunosuppressive and pro-tumor character of tumor 
microenvironment (Hussein 2004; Chen et al. 2011). Among inflammatory cells, 
V.  
 
70 
 
macrophages are of pivotal importance in malignancy development, being specifically 
referred to as tumor-associated macrophages (TAMs) (Chen et al. 2011). TAMs are the 
most abundant leukocytes in the melanoma and their presence represent a poor 
prognostic (Brocker et al. 1988; Bernengo et al. 2000; Makitie et al. 2001; Varney et al. 
2005), due to induction of an immunosuppressive microenvironment that, among other 
consequences, inhibits tumor-specific CD8+ T cell-mediated cytotoxicity (Kono et al. 1996; 
Wang et al. 2012c). 
The growing understanding of immune involvement in tumorigenesis, contributed to 
therapies aiming immunologic targets (Dranoff 2009; Raaijmakers et al. 2013). However 
some of these therapies are only effective in a brief period of time while others have 
considerable side effects (Hodi et al. 2010; Solit and Rosen 2011; Graziani et al. 2012). 
Obviously, it is important to find new therapies for melanoma that target multiple 
biochemical pathways, in order to avoid tumor escape mechanisms (Smalley et al. 2006). 
 Prenylated xanthones, including alpha-mangostin (α-MG) (Figure 9), the most studied 
and abundant xanthone present on mangosteen pericarp (Garcinia mangostana Linn), 
have been associated to multiple benefits in several pathological conditions. In cancer, its 
effect is through the alteration of a significant number of physiological pathways, 
comprising the influence in immune system (Obolskiy et al. 2009; Shan et al. 2011; 
Gutierrez-Orozco and Failla 2013). Beside the previous reports of α-MG effect in immune 
functions, as far as we know the interference of this xanthone in the immune system 
microenvironment of melanoma has never been studied. 
Recently, a number of evidences suggested that α-MG has a potent antitumor effect 
against melanoma. These reports evaluated the effect of the compound in different 
melanoma cell lines (B16-F10 murine cell line, SK-MEL-28 human cell line) and described 
induction of apoptosis, cell cycle arrest and differentiation, and inhibition of both cell 
proliferation and metastasis (Wang et al. 2011; Wang et al. 2012a; Wang et al. 2012b; 
Wang et al. 2013). During the development of this study, Beninati et al  reported some 
experiments of α-MG effect on the A375 cell line (Beninati et al. 2014).  
In spite of these insights, and as far as we know, no studies on α-MG-dependent 
modulation of the immune microenvironment and its effect on melanoma growth were 
performed. 
Due to the importance of immune targets in melanoma therapies, the aim of the 
present work is to study α-MG effects on the immune system in order to potentiate its 
antitumor effect on A375-C5 melanoma cell line.  
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Figure 9: alpha-Mangostin 
 
Material and Methods 
Chemicals and reagents 
Reagents used in cell culture, including RPMI-1640, DMEM medium, and fetal bovine 
serum (FBS) were purchased from Gibco® Invitrogen Co. (Barcelona, Spain), 2-
mercaptoethanol for synthesis was obtained from Merck (Whitehouse Station, NJ, USA) 
and Glutamine cell culture grade and Dimethyl sulfoxide (DMSO) from Applichem 
(Darmstadt, Germany). N.N-Dimetilformamida (DMF) was acquiring from Spectramol 
Science Incorporated. 
Reagents used in SRB assay as Trichloroacetic acid (TCA), Acetic acid glacial 99-
100% and Trizma base were purchased from Prolabo (Oeiras, Portugal), CHEM-LAB 
(Zedelgem, Belgium) and Frilabo (Maia, Portugal), respectively. 
IL-1β, IL-10, TNF-α and TGF-β1 ELISA Ready-Set-Go Kits were acquired from 
eBioscience (San Diego, CA, USA). 
All other chemicals of analytical grade used in the experiments and unless otherwise 
indicated were purchased from Sigma-Aldrich® (St. Louis, MO, USA). 
 
Xanthones 
Alpha-mangostin (α-MG) was obtained from Sigma-Aldrich® (ref.M3824) and stock 
solution kept at -20ºC in DMSO. Just prior each assay, stock solution was diluted in 
appropriate complete medium to the maximum concentration to test and 1:2 dilutions were 
serially prepared. 
 
Cell lines 
A375-C5 human malignant melanoma cell line and RAW 264.7 mouse macrophage 
cell line are part of CEQUIMED cell culture collection. THP-1 human monocyte cell line 
was a courtesy of Rui Appelberg. 
A375-C5 was routinely maintained in 25 cm2 flasks containing RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 1 µL mL -1 Gentamycin at 37ºC in a 
humidified incubator with 5% CO2. For the THP-1 cell line the culture medium just 
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described was also supplemented with 0.05 mM 2-mercaptoethanol. RAW 264.7 cell line 
was maintained in 75 cm2 flasks containing DMEM medium with 10% FBS and 
gentamycin, in the same culture conditions. 
Cell lines were sub-cultured every 2 or 3 days by trypsinization (A375-C5), replacement 
of the medium (THP-1) or scraping (RAW 264.7) and used for each experiment when cells 
were in exponential growth. 
Human mononuclear cells were isolated from peripheral blood of healthy volunteers by 
Histopaque-1077 density centrifugation according to manufactures’ instructions. Informed 
consent was obtained from each volunteer. Cells were ressuspended in RPMI medium 
supplemented with 10% FBS and 1 µL mL-1 gentamycin. 
 
NO production assay 
The determination of nitric oxide (NO) production by RAW 264.7 (1 X 106 cells mL-1) 
after treatment and stimulation with 1.5 µg mL-1 LPS was quantified by Griess assay  as 
previous described by our group (Teixeira et al. 2005; Cerqueira et al. 2008). N-nitro-L-
arginine methyl ester (L-NAME), an inhibitor of inductive nitric oxide synthase (iNOS) 
activity and Dexamethasone, an inhibitor of iNOS expression, were used as positive 
controls. 
Since inhibition of NO production could be a consequence of an inhibition of iNOS 
expression and/or activity, it was necessary to investigate α-MG mechanism. For that, the 
compound was also added 6h and 14h after RAW 264.7 macrophages stimulation with 
LPS (Cerqueira et al. 2008). 
 
NO Scavenging assay 
To discard NO scavenging effect by xanthone, nitrite was chemically generated using 
sodium nitroprusside as previously described. Nitrite was quantified by Griess assay 
(Teixeira et al. 2005; Cerqueira et al. 2008). 
 
Human mononuclear cells MTT-proliferation assay 
Human mononuclear cells isolated from peripheral blood were plated (2-3 X 106 cell 
mL-1), treated with serial dilutions of xanthone, stimulated with 10 µg mL-1 
phytohemaglutinin (PHA) and incubated for 96h. After incubation, the MTT-proliferation 
assay was performed and absorbance measured at 550 nm. Cyclosporin A was used as 
positive control (Pedro et al. 2002; Cerqueira et al. 2003; Teixeira et al. 2005). 
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Cytokine quantification 
Culture supernatants of differentiated THP-1 cells, stimulated and treated as previously 
described, were stored at -20ºC until cytokine analyses.  
Levels of interleukin-1β (IL-1β), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) 
and transforming growth factor-β1 (TGFβ1) in culture supernatants were quantified by 
ELISA Ready-Set-Go Kits (eBioscience) according to manufacturers’ instructions and 
measured at 510 nm in an ELISA reader (Stat Fax 3200, Awareness Technology) 
(Cerqueira et al. 2003). 
The same cytokines were also evaluated in supernatants from peripheral mononuclear 
cells. Cells were stimulated with PHA, treated with tree concentrations of α-MG and 
incubated for 48h. Then, supernatants were collected and stored until analysis (Cerqueira 
et al. 2003; Lou et al. 2013). 
 
Sulphorrodamine B (SRB) growth tumor inhibition assay 
α-MG effect on the growth of A375-C5 human melanoma cell line (7,5 X 104 cells mL-1) 
was evaluated according to the method adopted by the National Cancer Institute (NCI, 
USA) (Monks et al. 1991), as already described by our group (Pedro et al. 2002; Gupta et 
al. 2008). Doxorubicin (1:10 dilutions) was used as positive control (Pedro et al. 2002; 
Gupta et al. 2008).  
 
Antitumor effect of conditioned macrophage culture medium 
After testing the cytotoxic effect of α-MG on A375-C5 melanoma cell line, the antitumor 
effect of conditioned macrophage culture medium was evaluated according to He et al, 
2012. Briefly, THP-1 cell line was plated at 1 X 105 cells mL-1 and differentiated into THP-1 
macrophages with 10 ng mL-1 PMA for 72h (He et al. 2012). Once differentiated, cells 
were washed twice with complete medium and left for another 24h incubation in order to 
obtain the resting state of macrophages (Chanput et al. 2012; Chanput et al. 2014). Then, 
they were stimulated with 100 µL of LPS solution (1 µg mL-1) and treated with 100 µL α-
MG (concentration below GI50). Treated cell were incubated for 24h at 37ºC, 5% CO2 in a 
humidified incubator (He et al. 2012). Plates were centrifuged and half of the volume of 
each well was transferred to A375-C5 adherent cell monolayers, previously plated as 
described for tumor growth inhibition assay procedure. After 48h incubation, SRB assay 
was performed, absorbance was measured and cell-growth inhibition determined (Pedro 
et al. 2002). 
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MTT-viability assay 
Toxicity of α-MG on THP-1 cell line, human mononuclear cells and RAW 254.7 cell line 
was evaluated by MTT-viability assay (Pedro et al. 2002; Cerqueira et al. 2003; Teixeira et 
al. 2005). 
 
Statistical analysis 
Except otherwise stated, results are the mean ± SEM of at least three independent 
experiments, performed in duplicate. Statistical analysis was performed with SPSS for 
Windows (version 20.0). Statistical significance between groups was calculated by Mann-
Whitney Test and it is considered significant for p values less than 0.05. 
 
Ethics 
Ethics approval was obtained by the Ethic Comity of University Fernando Pessoa. 
 
Results 
Effect on NO production by macrophages 
The production of NO by RAW 264.7 was strongly inhibited by α-MG (IC50 = 13.8 ± 0.7 
µM) in a dose-dependent manner (data not shown). Dexamethasone showed an IC50 of 
4.3 ± 0.6 μM (Table 2). To exclude cell death, MTT assay was performed and exposed 
that viability was higher that 90% for IC50, therefore, not responsible for the decrease in 
NO production (Table 2). Scavenging of NO, was not detected since the NO production in 
presence and absence of α-MG was similar (data not show). This finds, indicating that 
scavenging could not be responsible for the 50% reduction of NO production in RAW 
264.7 cell line. 
 
Table 2: Effect of α-MG on NO production by LPS-stimulated RAW 264.7 macrophages. 
 NO inhibition (IC50) Viability at IC50 
Alpha-mangostin 13.8 ± 0.7 µM 91.3 ± 3.7 % 
L-Name 62.4 ± 7.8 μM 96.0 ±  2.5 % 
Dexamethasone 4.3 ± 0.6 μM 100 % 
Results are the mean ± SEM (n = 3). L-Name and Dexamethasone was used as positive control. 
 
It was next investigated whether the inhibition of NO production was due to a decrease 
in iNOS expression or impairment of iNOS activity. iNOS is transcribed within 2-4 hours 
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and translated within six hours after LPS-stimulation in macrophages (Xie et al. 1994). As 
such, α-MG was added at a concentration close to IC50 value and NO was measured at 0, 
6 or 14 h after RAW 264.7 macrophages stimulation with LPS. When α-MG was added 
simultaneously with the stimulus, about 50% of NO production was inhibited. When the 
compound was added 6 h after stimulation, the effect on iNOS was not detected (Table 
3). This finds, support the hypothesis that the compound act in the first hours after LPS 
stimulation. 
Once again, toxicity was excluded by MTT viability assay, since cells showed viability 
higher than 90% at dilution closest to IC50 of α-MG. Concentrations of xanthone and 
controls (L-NAME and Dexamethasone) used in this study was the dilution closest to IC50. 
 
Table 3: Inhibitory effect of α-MG on NO production by RAW264.7. 
 
NO inhibition (% of control) 
0 h 6 h 14 h 
α-MG at 12,5 μM 44.7  ±  3.2 % n.i. n.i. 
L-Name at 62,5 μM 52.1 ± 6.0 % 50.7 ± 3.8 % 
┼
 24.7 ± 3.1 % * 
Dexamethasone at 6,25 μM 55.9 ± 2.3 % 15.7 ± 6.0 % * n.i. 
Macrophages were exposed to LPS and treated with the alpha-mangostin at different times after stimulation: 0 
h (simultaneously with the stimulus), 6 h and 14 h after stimulation. Results are the mean ± SEM (n = 3). n.i.= 
no inhibition. * p < 0.001, 
┼
 p > 0.05. L-NAME and Dexamethasone was used as positive controls. 
 
 
Effects of α-MG on macrophage production of IL-1β, IL-10, TGF-β1 and TNF-α  
Further experiments were carried out to determine the effect of α-MG on the production 
of four cytokines by LPS-stimulated THP-1 macrophages cell line. Two concentrations of 
the compound (below GI50) were studied in order to conduct a dose-response study and 
evaluate the effect of this xanthone on the kinetics of cytokine production. 
A significant decrease in the production of IL-1β, TGF-β1 was observed for the two 
concentrations of α-MG tested in macrophages, as compared to α-MG-untreated 
macrophages, while an augment of TNF-α was detected. IL-10 expression was not 
affected (Figure 10). 
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Figure 10: Production of IL-1β, IL-10, TGF-β1 and TNF-α by THP-1 macrophages. Cytokine production was 
evaluated on unstimulated macrophages (basal), LPS-stimulated macrophages and macrophages treated with 
3 and 6 µM of alpha-mangostin. Data are the mean ± SEM from tree independent experiments performed in 
duplicate. * p < 0.001; 
┼
 p > 0.05. 
 
Effects on lymphocyte proliferation 
The effect of α-MG on the mitogenic response of peripheral human lymphocytes to 
PHA, was evaluated (Table 4) and measured in concentration corresponding to 50 % 
inhibition of proliferation (IC50). The compound strongly inhibited lymphocytes proliferation 
in a dose-dependent manner (data not show).  
No lymphocytoxicity was observed when the human lymphocytes were exposed to the 
IC50 concentrations of these xanthones (cell viability near to 100%), which leads to the 
conclusion that its inhibitory activity was associated with cell proliferation rather than to a 
toxic effect (data not shown). 
 
Table 4: Effect of α-MG on the PHA-induced proliferation on human lymphocytes 
 
 
Proliferation (IC
50
) 
Alpha-mangostin 9.2 ± 0.3 µM 
Cyclosporin A 0.1 ± 0.4 X 10
-2
 µM 
Cyclosporin A was used as positive control. Results are the mean ± SEM of 3 independent experiments in 
duplicate. 
 
α
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β1
Figure 11: Production of IL-1β, IL-10, TGF-β1 and TNF-α by PHA-stimulated human mononuclear cells. 
Cytokines production was evaluated on unstimulated lymphocutes (basal), PHA-stimulated lymphocytes and 
lymphocytes treated with 5, 10 and 20 µM of α-mangostin. Data are the mean ± SEM from tree independent 
experiments, performed in duplicate. * p < 0.001. 
Effects of α-MG on lymphocyte production of IL-1β, IL-10, TGF-β1 and TNF-α 
The effect of α-MG at three concentration (below, above and IC50) on cytokine 
production by PHA-simulated human mononuclear cells from peripheral blood was 
evaluated (Figure 11). At 20 µM (above IC50) the compound showed a strong inhibition of 
IL-10 and TNF-α production and induction of TGF-β1 but no effects were detected at 
lower concentrations. The compound did not affect the production of IL-1β by PHA-
stimulated lymphocytes compared with stimulated non-treated cells (positive control). No 
toxicity on lymphocytes was observed for the concentrations tested (viability > to 80%). 
 
 
Effect of α-MG on melanoma growth 
The cell growth inhibitory effect of α-MG was examined against A375-C5 cell line. This 
xanthone is a potent inhibitor of the growth of A375-C5 (Table 5) in a dose-dependent 
manner (data not show).  
 
Table 5: Effects of α-mangostin on the growth of A375-C5 human melanoma cell line. 
 Growth inhibition (GI50) 
Alpha-mangostin 11.3 ± 0.9 µM 
Doxorrubicin 1.8 X 10-3  ± 0.4 X 10-3 µM 
Results are the mean ± SEM (n = 3). Doxorrubicin was used as positive control. 
α
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Antitumor effect of conditioned macrophage culture medium 
As modulation of the immune system has been a promising approach in melanoma 
treatment. It was investigated the possible influence of conditioned macrophage 
supernatants on A375-C5 cells growth to teste the influence of soluble immunologic 
factors produced by macrophages on melanoma cell line. 
A significant (p < 0.001) decrease in melanoma cell growth was observed after 
exposure to supernatants from both α-MG-treated and untreated THP-1 macrophages 
(Figure 12), which is in favor of an α-MG-independent anti-tumor effect of soluble 
mediators produced by cultured THP-1 macrophages. 
 
 
 
Figure 12: Antitumor effect of alpha-mangostin, macrophages supernatants and alpha-mangostin conditioned 
macrophage culture medium on A375-C5 melanoma cell line. THP-1 PMA-differentiated macrophages were 
treated with xanthone and supernatants were added to melanoma cells. Results show mean values ± SEM (n 
= 3). * p < 0.001 
 
Discussion 
Natural xanthones, including those from mangosteen extract have antitumor and 
immunomodulatory effects (Pinto et al. 2005; Obolskiy et al. 2009; Shan et al. 2011; 
Gutierrez-Orozco and Failla 2013). In particular, alpha-mangostin has been repeatedly 
associated with modulation of a great variety of physiologic pathways, including 
inflammation. These findings reinforce their antitumor potential, fighting tumor progression 
and treatment resistance (Pinto et al. 2005; Shan et al. 2011; Gutierrez-Orozco and Failla 
2013). 
In melanoma, several evidences reported the potential of immune targets as 
therapeutic agents. This facts result in the current use of ipilimumab, an 
immunomodulating antibody that target CTLA4 on activated T cells and inhibit regulatory 
T cells, in spite of the severe toxicity associated (Hodi et al. 2010; Graziani et al. 2012).  
The character highly immunogenic of melanocytic tumors and the influence of host 
immune response and microenvironment inflammatory cells in cancer growth were 
 Growth inhibition 
(% of control) 
Alpha-mangostin  
(6,25 μM) 
5.4 ± 2.9 % 
Macrophages supernatants 
 
25.0 ± 2.5 % * 
 
α-MG (6,25 μM) conditioned 
macrophages supernatants 
24.4 ± 2.7 % * 
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verified (Hussein 2004; Dranoff 2009; Chen et al. 2011). Indeed, primary melanomas 
undergo spontaneous regression much more frequently than any other cancer that may 
be a sign of immunosurveillance or, by other way, it may be due melanoma are easier to 
visualize (Printz 2001; Kalialis et al. 2009). Nevertheless, other evidences corroborate the 
involvement of immune system, namely the relatively amount of tumor-infiltrating 
lymphocytes in melanoma microenvironment compared with other cancers and associated 
with favorable prognostic (Maio 2012; Kushnir and Merimsky 2013) and the appearance of 
autoimmune condition as vitiligo in melanoma patients or patients treated with 
immunotherapy which normally means a better disease outcome (Le Gal et al. 2001; 
Phan et al. 2001; Boasberg et al. 2006). In more advanced stages, this cancer became 
capable to avoid immunosurveillance (Reiman et al. 2007; Speeckaert et al. 2011) and its 
progression and metastatic potential may be supported by immune cells present in tumor 
microenvironment, as the tumor-associated macrophages (TAMs) since they are the most 
abundant leucocytes in melanoma and represent a poor prognostic (Brocker et al. 1988; 
Bernengo et al. 2000; Makitie et al. 2001; Varney et al. 2005; Porta et al. 2007; Solinas et 
al. 2009; Mantovani and Sica 2010; Qian and Pollard 2010). 
In spite of the verified interaction of immune system in melanoma treatment and the 
potential of xanthones as antitumor and immunomodulatory agent, any research was 
based on the direct effect of any immune cell treated with xanthonic compounds in the 
tumor growth. 
According to the established influence of inflammation on cancer (induces 
carcinogenisis, tumor progression and promotes angiogenisis) (Apte and Voronov 2008; 
Germano et al. 2008; Kundu and Surh 2008; Colotta et al. 2009; Mantovani 2010) and 
particularly in melanoma, it was investigated the potential effect of the compound in 
different immune pathways in human and murine macrophage cell lines and human 
mononuclear cells from peripheral blood. Indeed, α-MG inhibited NO production and TNF-
α secretion by murine macrophages cells (Chen et al. 2008; Tewtrakul et al. 2009). In 
spite of that finds, any studies were performed in the cytokines interleukin - 1β (IL-1β), IL-
10, the tumor grow factor - β1 (TGF-β1) and the tumor necrosis factor - α  (TNF- α) in 
THP-1 macrophages as performed in this paper. 
RAW 264.7 was used for investigation of NO production, since this cell line was 
referred as an appropriate model to study iNOS system (Dirsch et al. 1998; Shih et al. 
2010). Human macrophages in vitro produce low quantity of NO in response to stimuli 
(Thomassen and Kavuru 2001). However, either in vitro murine cells and in vivo human 
macrophages express great quantities of NO in inflammatory conditions (Ochoa et al. 
1991; Dirsch et al. 1998) 
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α-MG was a strong inhibitor of NO production by LPS-stimulated RAW 264.7 (IC50 = 
13.8 ± 0.7 µM). Since α-MG effect was not due to cell death or scavenging of chemicaly 
generated NO, it may act at the level of NO production by iNOS. 
In inflammatory process, NO is produced by inducible NO synthetase (iNOS or NOS2) 
from L-arginine and molecular oxygen (Gross and Wolin 1995; Aramaki 2000). The 
inductible form is stimulated by imunologic factors and expressed in virtually all cells 
(Gross and Wolin 1995). In macrophages, its production is stimulated by a number of 
cytokines and LPS (Lowenstein et al. 1993; Gross and Wolin 1995). Production of NO 
could be a consequence of iNOS regulation at transcriptional and post-transcriptional 
level, depending of gene transcription, stability and translation of mRNA, stability of the 
protein, availability of substrates or co-factors, inhibitors that compete with substrates and 
the known NO feedback effect (Nathan and Xie 1994; Bogdan et al. 2000; Brunet 2001).   
Therefore, the underlying mechanism to α-MG inhibition of NO production needed 
further investigation. For that, α-MG was added at different hours: 0h (simultaneously), 6h 
and 14h after RAW 264.7 macrophages stimulation with LPS. 
In spite of α-MG exhibit a potent inhibition of NO production when added 
simultaneously with LPS-stimulation, this production remained stable either when it was 
added 6 or 14h after stimulation. This findings suggest an interference on iNOS 
expression since the enzyme is transcribed within 2-4 hours and translated within six 
hours after LPS-stimulation in macrophages (Xie et al. 1994). L-NAME (inhibitor of iNOS 
activity) (McCall et al. 1991), and Dexamethasone, inhibitor of iNOS expression 
(Korhonen et al. 2002) was used as positive controls and the obtained results was in 
accordance with the mechanism proposed to these inhibitors by our technique.  
In accordance to our finds, Chen et al and Tewtrakul et al reported an inhibition of 
iNOS mRNA expression on RAW 264.7 macrophages by α-MG.  
Inhibition of iNOS expression indicates an anti-inflammatory potential of α-MG. 
However, in cancer, this inhibition represents controversial effects because NO has been 
reported as cytotoxic in melanoma and many other tumors, but simultaneously it 
modulates many pro-tumor pathways including resistance to apoptosis, cell cycle 
progression, angiogenesis invasion, and metastasis (Ying and Hofseth 2007; Choudhari 
et al. 2013). So, the result of α-MG-dependent inhibition of NO production for melanoma 
progression needs further investigation. 
Macrophages, including TAMs, are dynamic and heterogeneous cells mainly due to 
their capacity to respond to stimulus. According to the microenvironment they may be 
polarized into a spectrum of phenotypes between the extremes M1 (classic) and M2 
(alternative). M1 macrophages produced high levels of iNOS, TNF-α, IL-1β and other pro-
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inflammatory molecules, while M2 macrophages are immunosuppressive, significantly 
expressing IL-10 and TGF-β (Allavena et al. 2008; Biswas et al. 2013).  
Several evidences indicate that macrophage phenotypes can change during tumor 
progression (Zaynagetdinov et al. 2011). M1 activation may induce chronic inflammation, 
a factor that could predispose to tumor initiation (Greten et al. 2004; Pikarsky et al. 2004). 
However, in early stages of tumor progression, TAMs adopt an M1-like phenotype that 
contributes to anti-tumor immunity. M2 phenotype is mainly expressed in established 
tumors and induce immunosuppressive, angiogenic and metastatic effects (Mantovani et 
al. 2004; Sica et al. 2006; Gordon and Mantovani 2011; Zaynagetdinov et al. 2011; Liao et 
al. 2014).  
α-MG had a dual influence on the immune system, either inhibiting IL-1β and NO 
responses, or inhibiting TGF-β1 and stimulating TNF-α expression.  
IL-1β, a pro-inflammatory cytokine mainly produced by monocytes and macrophages is 
an example of the pleiotropism of immune system. In melanoma its expression was 
associated to tumor progression and promotion of lung metastases from melanoma 
(Giavazzi et al. 1990; Meyer et al. 2011). Therefore, IL-1β has been associated with all 
steps of malignancy (carcinogenesis, progression, invasion and metastasis) and may 
even be expressed by the tumor cells (Apte and Voronov 2008). In contrast, M1 
macrophages phenotype produced interleukin induce an immune response against 
malignant cells (Fairweather and Cihakova 2009). Considering all that was stated above, 
the inhibition of IL-1β mediated by α-MG could be beneficial so this cytokine induces 
tumor progression and metastasis. Melanoma is a highly metastatic kind of cancer 
contributing to the high mortality associated (Kuphal and Bosserhoff 2009; Raaijmakers et 
al. 2013), therefore a therapy that suppress or control angiogenesis and invasion may be 
an important approach. 
TGF-β1 regulates multiple cellular processes, including proliferation and differentiation. 
It acts as a potent inducer of differentiation in normal cells which leads to the concept that 
this cytokine protects against cancer in early stages of carcinogenesis (Yang et al. 2008). 
By the other hand, several tumors express increasing amounts of TGF-β1 which is 
associated with disease progression, invasion and metastasis both in vivo and in vitro 
(Akhurst and Derynck 2001). In melanoma, TGF-β isoforms (TGF-β1/2/3) are highly 
expressed and increase in parallel with tumor progression (Krasagakis et al. 1998; 
Javelaud et al. 2008). According to that, this cytokine is commonly produced by M2-like 
macrophages leads to a Th2 response, i.e., promotes an immunosuppressive 
microenvironment that allows the tumor immune escape (Coffelt et al. 2009; Martinez et 
al. 2009; Siveen and Kuttan 2009; Hao et al. 2012; Sica and Mantovani 2012). The 
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inhibition of TGF-β1 by α-MG may benefit the treatment of melanoma, mainly in later 
stages of tumorigenesis.  
TNF-α stimulation predicts a favorable outcome in melanoma treatment since several 
reports associated the use of TNF inhibitors as a factor that appear to increase the risk of 
skin cancer, including melanoma (Mariette et al. 2011; Kouklakis et al. 2013). In spite of 
that, the concentration expressed by THP-1 cells was minimal even in LPS-stimulated and 
non-treated macrophages. 
IL-10 is an anti-inflammatory cytokine able to induce tumor progression through the 
promotion of angiogenesis and suppression of immune surveillance. In melanoma, its 
influence facilitates metastasis formation (García-Hernández et al. 2002; Itakura et al. 
2011). In the present study, it was observed no alteration on IL-10 concentration after 
treatment with α-MG. 
Taking into account the pattern of cytokines altered by the treatment with α-MG, it was 
inferred the potential underling mechanism of iNOS inhibition by xanthone. NOS2 gene 
expression and translation was stimulated by a number of pro-inflammatory cytokines, 
particularly TNF-α, IL-1β and IFN-γ, compounds of bacterial origin as LPS (Nathan 1992) 
and stress signaling as hypoxia (Ferreiro et al. 2001). These stimuli may activate NF-κB or 
JAK-STAT (janus tyrosine kinase - signal transducers and activators of transcription) 
pathways (Kleinert et al. 1998; Xuan et al. 2001). Additionally, MAPK pathway most likely 
contributes to iNOS expression (Janssen-Heininger et al. 1999; Chan et al. 2001). It is 
also known that TGF-β1 inhibits iNOS expression by mRNA destabilization (Perrella et al. 
1994). NF-κB pathway contributes to iNOS synthesis and upregulate IL-1β level. α-MG 
treated THP-1 macrophages expressed lower IL-1β and NO levels comparatively to 
control cells leading us to hypothesize the interference of the xanthone with NF-κB 
pathway. More studies must be performed in order to corroborate this supposition. 
Macrophage activation and polarization are triggered by T helper cells (Th1 induce M1 
phenotype and Th2 the M2-like phenotype). In turn, M1 macrophages recruit Th1 cells, 
CD8+ CTL (cytotoxic T cells) and NK cells leading to an inflammatory response and 
antitumor immunity, while M2-like macrophages favor the recruitment and development of 
Treg (regulatory T cells) and Th2, leading to a response that supports tumor growth 
through immunosuppression (Mantovani et al. 2002; Mantovani et al. 2004; Martinez et al. 
2009; Siveen and Kuttan 2009; Sica and Mantovani 2012). In order to complement the 
described effect of α-MG on the immune microenvironment of melanoma, a study in 
influence of the compound in proliferation and cytokines production by human 
lymphocytes was performed. The compound strongly inhibit PHA-stimulated human 
mononuclear cells proliferation.  
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As weel as discussed to macrophages, lymphocytes have divergent roles in cancer 
due to their plasticity (Lakshmi Narendra et al. 2013). With the aim of establish the impact 
of proliferation inhibition in tumors, a set of four cytokines was evaluated in PHA-
stimulated mononuclear cells from peripheral blood. At IC50 (≃ 10 µM) concentration of α-
MG any cytokine concentration was altered. IL-10 and TNF-α was reduced to basal levels 
and TGF-β1 was stimulated at twice IC50 concentration. This finds indicate and absent 
effect of α-MG in T lymphocytes at concentrations required for inhibition of melanoma 
cells growth and for the immunomodulatory influence in macrophages which may indicate 
no significant impact of lymphocytes treated with α-MG on melanoma growth inhibition or 
in modulating of macrophages. Recently, Kasemwattanaroj et al, 2013 reported no 
alteration in IL-1β and TNF-α expression levels by conavalin A stimulated human 
mononuclear cells treated with α-MG (Kasemwattanaroj et al. 2013). 
Considering the results of cytokines modulation in THP-1 human macrophages 
mediated by α-MG and the established involvement of immune system in melanoma 
treatment (Brocker et al. 1988; Bernengo et al. 2000; Makitie et al. 2001; Varney et al. 
2005; Porta et al. 2007; Solinas et al. 2009; Mantovani and Sica 2010; Qian and Pollard 
2010), it was hyphotisised if condicioned macrophages culture medium may potentiate the 
cytotoxic activity of α-MG. Anticancer effect of α-MG was previously evaluated in different 
melanoma cell lines (Wang et al. 2011; Wang et al. 2012a; Wang et al. 2012b; Wang et al. 
2013; Beninati et al. 2014). In this work, the antitumor activity of α-MG on melanoma 
A375-C5 cells was determined and compared with that of α-MG treated macrophages 
supernatants. α-MG strongly inhibited melanoma growth (GI50 = 11.3 ± 0.9 µM). The 
results also demonstrated that the supernatants od THP-1 macrophages either treated or 
not with α-MG significantly interfere with melanoma cell growth. This results prove that the 
immune microenvironment created by macrophages associated to tumors interfere with 
tumor cell viability. For α-MG dose tested (6.25 µM), below GI50 concentration, no 
significantly differences were observed for the cytotoxic activity of macrophages 
supernatants, when treated or not with xanthone. 
However, it was proved that α-MG interferes with cytokine and NO production by 
activated macrophages leading to the evidence that the xanthone interferes with immune 
microenvironment of the tumor. Therefore, it was expected a difference between the 
cytotoxic effect of treated and non-treated macrophages supernatants. Our results could 
be due to the lower dose used since for 6.25 µM only a ≃ 5% inhibition of melanoma cell 
growth was observed. Althought, no higher doses could be used in the assays since they 
were associated with a significant loss of viability of THP-1 macrophages, as determined 
by the MTT assay. 
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Therefore, further studies in other in vitro or/and in vivo models must be performed in 
order to clarify the α-MG effect in melanoma treatment and consequently establish α-MG 
as a prospective co-adjuvant drug in these tumors. From this set of data find in this study 
it is possible to infer that α-MG could be very interesting agent for melanoma treatment. 
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Paper 3 (draft): “1,2-dihydroxyxanthone antitumor activity: 
cytotoxicity and influence on the immune system 
microenvironment” 
 
Abstract 
Xanthones has been suggested as prospective candidates for cancer treatment. In 
melanoma its potential anticancer activity is, not only, due to a direct cytotoxic effect, but 
also, due to immunomodulation, since melanoma is highly immunogenic. 
The main gold of this study was evaluate the 1,2-dihydroxyxanthone (i) cytotoxic effect 
on A375-C5 melanoma cell line and (ii) it interference with the immune macrophages 
induced microenvironment of the tumor. 
1,2-Dihydroxyxanthone showed a moderate inhibition of melanoma growth (GI50 = 55.0 
± 2.3 µM). However, it strongly interferes with THP-1 human macrophages immune 
microenvironment, resulting in a two-fold increase of the cytotoxic effect of macrophages 
on A375-C5 melanoma cells. 1,2-Dihydroxyxanthone also decreased the concentration of 
IL-1β  and stimulated TNF-α (characteristic cytokines of M1 phenotype) and  inhibited IL-
10 and increased TGF-β1 expression (characteristic cytokines of M2 phenotype). This 
xanthone also inhibited nitric oxide production (IC50 = 22.0 ± 0,9 µM) by RAW 264.7 
murine macrophages, possibly by inhibit the synthesis of inducible nitric oxide synthase.  
In conclusion, these finds allowed to infer a prospective impact of 1,2-
dihydroxyxanthone in melanoma treatment, not only due to cytotoxic effect but also due to 
immunomodulation of tumor microenvironment.  
 
Introduction 
Melanoma is originated from melanocytic cells and is a result a multistep 
tumorigenesis. In past years the involvement of immune system in this process has been 
pointed as the main factor for progression of malignancy (Hussein 2004; Chen et al. 
2011). According to that, many investigations have been focused on therapies with 
immune targets which result in the approved therapy Ipilimumab (inhibitor of the 
immunosuppressive regulatory T cells) (Dranoff 2009; Raaijmakers et al. 2013). However, 
the actual therapies, standard or alternatives are only effectives for a brief period of time 
due to escape mechanisms, and/or are associated with severe side effects (Hodi et al. 
2010; Solit and Rosen 2011; Graziani et al. 2012). 
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Nowadays, there is a need to find more efficient and safe alternative treatments that 
target multiple pathways to prevent refractory tumor and consequently avoid the massive 
mortality rate associated to melanoma (Kuphal and Bosserhoff 2009; Gast et al. 2011; 
Raaijmakers et al. 2013). 
The investigation in xanthonic compounds has been rising mostly due to their 
remarkable characteristics in the improvement of human health (Pinto et al. 2005; Pinto 
and Castanheiro 2009). Xanthones from natural origin are, in fact, very promising 
compounds, however, are limited in position or type of constituents due to the biosynthetic 
pathways. Synthesis of new xanthones is important to enlarge the diversity of compounds 
and increase the possibility of biological activities, creating compounds with better 
therapeutic proprieties (Pedro et al. 2002). 
Our group has a vast experience in the syntheses of xanthonic derivatives. 1,2-
dihidroxyxanthone (1,2-DHX) (Figure 13) was obtained by demethylation of 1,2-
dimethoxyxanthone according to the described procedure (48%) (Gottlieb et al. 1970; 
Vermes et al. 1985). The antitumor activity of this compound was already evaluated in 
three cancer cell lines, namely UACC-62 (melanoma), MCF-7 (breast) and TK-10 (renal), 
showing specificity for melanoma cells (Pedro et al. 2002; Sousa et al. 2002). Studies of 
this compound were also carrying out in T lymphocytes and demonstrated a weak, but 
present, inhibition of their proliferation (Pedro et al. 2002; Sousa et al. 2002). 
As immune system, mainly the tumor-associated macrophages (TAMs), are important 
in melanoma therapies, not only because the highly immunogenic character of 
melanocytic tumors, but also because macrophages are the most abundant immune cell 
present in the tumor (Brocker et al. 1988; Bernengo et al. 2000; Makitie et al. 2001; 
Varney et al. 2005; Porta et al. 2007; Solinas et al. 2009; Mantovani and Sica 2010; Qian 
and Pollard 2010). The cytotoxic activity of 1,2-DHX against A375-C5 melanoma epithelial 
cell line and its interference in immunomodulation of THP-1 macrophages was evaluated. 
 
 
Figure 13: 1,2-Dihydroxyxanthone 
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Material and Methods 
Chemicals and reagents 
Reagents used in cell culture, including RPMI-1640, DMEM medium, and fetal bovine 
serum (FBS) were purchased from Gibco® Invitrogen Co. (Barcelona, Spain), 2-
mercaptoethanol for synthesis was obtained from Merck (Whitehouse Station, NJ, USA), 
Glutamine cell culture grade and Dimethyl sulfoxide (DMSO) from Applichem (Darmstadt, 
Germany). N.N-Dimetilformamida (DMF) was acquiring from Spectramol Science 
Incorporated. 
Reagents used in SRB assay as Trichloroacetic acid (TCA), Acetic acid glacial 99-
100% and Trizma base were purchased from Prolabo (Oeiras, Portugal), CHEM-LAB 
(Zedelgem, Belgium) and Frilabo (Maia, Portugal), respectively. 
IL-1β, IL-10, TNF-α and TGF-β1 ELISA Ready-Set-Go Kits were acquiered from 
eBioscience (San Diego, CA, USA). 
All other chemicals of analytical grade used in the experiments and unless otherwise 
indicated were purchased from Sigma-Aldrich® (St. Louis, MO, USA). 
 
Xanthone 
1,2-Dihydroxyxanthone (1,2-DHX) was synthetized in Laboratory of Organic and 
Pharmaceutic Chemistry (Faculty of Pharmacy, University of Porto) and in CEQUIMED 
(Centro de Química Medicinal; University of Porto) as previously described (Gales et al. 
2001) and stock solution kept at -20ºC in DMSO. Just prior each assay, stock solution was 
diluted in appropriate complete medium to the maximum concentration to test and 1:2 
dilutions were serially prepared. 
 
Cell lines 
A375-C5 human malignant melanoma cell line and RAW 264.7 mouse macrophage 
cell line are part of CEQUIMED cell culture collection. THP-1 human monocyte cell line 
was a courtesy of Rui Appelberg.  
A375-C5 was routinely maintained in 25 cm2 flasks containing RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 1 µL mL -1 Gentamycin at 37ºC in a 
humidified incubator with 5% CO2. For the THP-1 cell line the culture medium just 
described was also supplemented with 0.05 mM 2-mercaptoethanol. RAW 264.7 cell line 
was maintained 75 cm2 flasks containing DMEM medium with the 10% FBS and 
gentamycin, in the same conditions. 
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Cell lines were sub-cultured every 2 or 3 days by trypsinization (A375-C5), replacement 
of the medium (THP-1) or scraping (RAW 264.7) and used for each experiment when the 
cells were in exponential growth. 
Human mononuclear cells were isolated from heparinized peripheral blood of healthy 
volunteers by Histopaque-1077 density centrifugation according to manufactures’ 
instruction. Informed consent was obtained from each volunteer. Cells were ressuspended 
in RPMI medium supplemented with 10% FBS and 1 µL mL-1 gentamycin. 
 
Sulphorrodamine B (SRB) growth inhibition assay 
1,2-DHX effect on the growth of A375-C5 human melanoma cell line (7,5 X 104 cells 
mL-1) was evaluated according to the method adopted by the National Cancer Institute 
(NCI, USA) (Monks et al. 1991) as already described by our group (Pedro et al. 2002; 
Gupta et al. 2008). Doxorubicin (1:10 dilutions) was used as positive control (Pedro et al. 
2002; Gupta et al. 2008).  
 
Antitumor effect of conditioned macrophages culture medium 
After testing the cytotoxic effect of 1,2-DHX on A375-C5 melanoma cell line, the 
antitumor effect of conditioned macrophage culture medium was evaluated according to 
He et al, 2012. Briefly, THP-1 cell line was plated at 1 X 105 cells  mL-1 and differentiated 
into THP-1 macrophages with 10 ng mL-1 PMA for 72h (He et al. 2012). Once 
differentiated, cells were washed twice with complete medium and left for another 24h 
incubation in order to obtain the resting stages of macrophages (Chanput et al. 2012; 
Chanput et al. 2014). Then, they were stimulated with 100 µL of LPS solution (1 µg mL -1) 
and treated with 100 µL 1,2-DHX (concentration below GI50). Treated cell were incubated 
for 24h at 37ºC, 5% CO2 in a humidified incubator (He et al. 2012). Plates were 
centrifuged and half of the volume of each well was transferred to A375-C5 adherent cell 
monolayers, previously plated as for cancer growth inhibition assay procedure. After 48h 
incubation, SRB assay was performed, absorbance was measured and cell-growth 
inhibition determinate (Pedro et al. 2002). 
 
Cytokine quantification 
Culture supernatants of differentiated THP-1 cells, stimulated and treated as previously 
described, were storage at -20ºC until cytokine analyses.  
Levels of interleukin-1β (IL-1β), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) 
and transforming growth factor-β1 (TGFβ1) in culture supernatants were quantified by 
ELISA Ready-Set-Go Kits (eBioscience) according to manufacturers’ instructions and 
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measured at 510 nm in an ELISA reader (Stat FAX3200, Awareness Technology) 
(Cerqueira et al. 2003). 
 
NO production assay 
The determination of nitric oxide (NO) production by RAW 264.7 (1 X 106 cells mL-1) 
after treatment and stimulation with 1.5 µg mL-1 LPS was quantified by Griess assay as 
previous described by our group (Teixeira et al. 2005; Cerqueira et al. 2008). N-nitro-L-
arginine methyl ester (L-NAME), and inhibitor of inductive nitric oxide synthase (iNOS) 
activity, and Dexamethasone, an inhibitor of iNOS expression, were used as positive 
controls. 
Since inhibition of NO production could be a consequence of an inhibition of iNOS 
expression and/or activity, it was necessary to investigate 1,2-DHX mechanism. For that, 
the compound was also added 6h and 14h after RAW 264.7 macrophages stimulation 
with LPS (Cerqueira et al. 2008). 
 
NO Scavenging assay 
To discard NO scavenging effect by xanthone, nitrite was chemically generated using 
sodium nitroprusside as previously described. Nitrite was quantified by Griess assay 
(Teixeira et al. 2005; Cerqueira et al. 2008). 
 
MTT-viability assay 
Toxicity of 1,2-DHX on THP-1 cell line and RAW 254.7 cell line was evaluated by MTT-
viability assay (Pedro et al. 2002; Cerqueira et al. 2003; Teixeira et al. 2005). 
 
Statistical analysis 
Except otherwise stated, results are the mean ± SEM of at least three independent 
experiments, performed in duplicate. Statistical analysis was performed with SPSS for 
Windows (version 20.0). Statistical significance between groups was calculated by Mann-
Whitney Test and it is considered for p values less than 0.05. 
 
Ethics 
Ethics approval was obtained by the Ethic Comity of University Fernando Pessoa. 
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Results 
Antitumor effect of 1,2-DHX and conditioned macrophages culture medium 
The evaluation of 1,2-DHX effect on A375-C5 melanoma growth was performed by 
SRB assay and revealed a moderate inhibitory effect of the xanthone (Table 6). This 
effect showed to be dose-dependent (data not show). 
 
Table 6: Effect of 1,2-dihydroxyxanthone on the growth of A375-C5 human melanoma cell line. 
 Growth inhibition (GI50) 
1,2-DHX 55.0 ±  2.3 µM 
Doxorrubicin 1.8 X 10-3  ± 0.4 X 10-3 µM 
Results are the mean ± SEM of three independent experiments performed in duplicate. Doxorrubicin was used 
as positive control. 
 
As modulation of immune system has been a promising approach in melanoma 
treatment, it was investigate the possible influence of 1,2-DHX conditioned macrophages 
supernatants on A375-C5 cells growth. 
The results demonstrated a similar inhibition of cancer cells growth by the compound at 
50 μM and non-treated macrophages. However, xanthone-treated macrophages-
conditioned medium showed a significant (p < 0,001) decrease of melanoma cell growth 
comparatively with the other two conditions, as demonstrated in  
Figure 14.  
 
 
 
Figure 14: Cytotoxic activity of 1,2-Dihydroyixanthone, macrophages supernatants and 1,2-
dihydroxyxanthone conditioned macrophages supernatants on A365-C5 melanoma cell line.THP-1 PHA-
differentiated macrophages were treated with the compound and supernatants were added to melanoma cells. 
Results show mean values ± SEM (n = 3). * p < 0.001 
 
 
Grow inhibition (% 
of control) 
1,2-DHX (50 μM) 31.6 ± 4.9 % 
Macrophages supernatants  25.0 ± 2.5 % 
1,2-DHX (50 μM) conditioned 
macrophages supernatants 
55.4 ± 4.4 % * 
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Effect on IL-1β, IL-10, TGF-β1 and TNF-α production by macrophages 
Further experiments were carried out to determine the underling mechanism of 1,2-
DHX on macrophages. Two concentrations of the compound (over and below GI50) were 
studied in order to evaluate the effect of this xanthone on the kinetics of cytokines 
production by LPS-stimulated THP-1 macrophages cell line (Figure 15). The expression 
of four cytokines was evaluated: IL-1β and TNF-α characteristic of M1 phenotype and IL-
10 and TGF-β1 characteristic of M2 phenotype. 
1,2-DHX significantly inhibited the expression of IL-1β and stimulated the expression of 
TNF-α at the two concentrations. At concentration above GI50, xanthone stimulated 
expression of TGF-β1 and suppressed IL-10 by THP-1 macrophages. 
 
Figure 15: Effect of 1,2-DHX on IL-1β, IL-10, TGF-β1 and TNF-α production by THP-1 macrophages. 
Cytokines production was evaluated on Unstimulates macrophages (basal), LPS-stimulated macrophages 
(positive control) and macrophages treated with 6 and 3 µM 1,2-dihydroxyxanthone. Data are the mean ± 
SEM from one experiment, performed with duplicate cultures, and it representative of tree experiments carried 
out independently. * p < 0.001; 
┼
 p > 0.05 
 
Effect on NO production by macrophages 
The production of NO by RAW 264.7 murine macrophages cell line was strongly 
inhibited by 1,2-DHX (IC50 = 22.0 ± 0.9 µM) (Table 7) in a dose-dependent manner (data 
not show). 
NO inhibiton was not associated to cell death since at IC50 values, viability was near 
100% (Table 7). 1,2-DHX did not show any scavenging activity of NO generated in a cell-
free system (data not show). 
 
 
α
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Table 7: Effect of 1,2-DHX on NO production by LPS-stimulated RAW 264.7 macrophages  
 
 
NO inhibition (IC50) Viability at IC50 
1,2-Dihydroxyxanthone 22.0 ± 0.9 µM 100 % 
L-Name 62.4 ± 7.8 μM 96.0 ±  2.5 % 
Dexamethasone 4.3 ± 0.6 μM 100 % 
Results are the mean ± SEM (n = 3). L-Name and Dexamethasone was used as positive control. 
 
It was next investigated whether the inhibition of NO production was due to a decrease 
in iNOS expression or impairment of iNOS activity. iNOS is transcribed within 2-4 hours 
and translated within six hours after LPS-stimulation in macrophages (Xie et al. 1994). As 
such, 1,2-DHX was added at a concentration close to IC50 value and NO was measured 
at 0, 6 and 14 h after RAW 264.7 macrophages stimulation with LPS. When 1,2-DHX was 
added simultaneously with the stimulus, about 57% of NO production was inhibited. When 
the compound was added 6 h after stimulation, the effect significantly decreased to 26% 
(p < 0.001), while a lack of inhibitory effect was observed when the compound was added 
14 h after stimulation (Table 8). 
Once again, toxicity was excluded by MTT viability assay, since cells showed viability 
higher than 90 % at dilution closest to IC50 of 1,2-DHX. Concentrations of xanthone and 
controls (L-NAME and Dexamethasone) used in this study were the dilution closest to 
IC50, previously determined. 
 
Table 8: Inhibitory effect of 1,2-DHX on NO production by RAW264.7. 
 
NO inhibition (% of control) 
0 h 6 h 14 h 
1,2-DHX at 25 μM 56.6  ±  1.8 % 25.0 ± 2.8 % * n.i. 
L-Name at 62,5 μM 52.1 ± 6.0 % 50.7 ± 3.8 % 
┼
 24.7 ± 3.1 % * 
Dexamethasone at 6,25 μM 55.9 ± 2.3 % 15.7 ± 6.0 % * n.i. 
Macrophages were exposed to LPS and treated with 1,2-dihydroxyxanthone at different times after 
stimulation: 0 h (simultaneously with the stimulus), 6 h and 14 h after stimulation. Results are the mean ± SEM 
(n = 3). n.i.= no inhibition. * p < 0.001, 
┼
 p > 0.05. L-NAME and Dexamethasone was used as positive controls. 
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Discussion 
The anticancer and immunomodulatory effect of natural and synthetic xanthones have 
been extensible reported in literature (Pinto et al. 2005; Teixeira et al. 2005; Castanheiro 
et al. 2007; Obolskiy et al. 2009; Gutierrez-Orozco and Failla 2013). In particular, 1,2-DHX 
inhibited the gowth of several cancer cell lines and  the proliferation of stimulated T 
lymphocytes (Pedro et al. 2002; Sousa et al. 2002). In spite of these insights, and as far 
as we know, no studies were performed considering the immune microenvironment of 1,2-
DHX-conditionated macrophages mediated effect on melanoma cell. 
In the present study, the effect of 1,2-DHX on A375-C5 melanoma cell line was 
evaluated. However, a significant difference of potency was observed when comparing 
the GI50 fot A375-C5  (GI50 = 55.0 ± 2.3 µM)  and UACC-62 melanoma cell line (GI50 = 
14.0 ± 0.3 µM), this may be explained by the  difference morphology of the cell, i.e. 
epithelial (A375-C5) and non-epethelial (UACC-62). 
Melanoma is a highly immunogenic tumor (Hussein 2004), therefore it was 
hyphotesised the possible improvement of anticancer capacity of 1,2-DHX by immune 
system involvement. It was showed that 1,2-DHX strongly interfere with macrophages 
immune microenvironment, resulting in a two-fold increase of the cytotoxic effect of 
macrophages on A375-C5 melanoma cells. This finds indicates a possible induction of an 
antitumor macrophages phenotype by 1,2-DHX since supernatants of non-treated 
macrophages by it self showed much lower inhibition comparatively to treated 
macrophages. 
In order to certify the underlying mechanism mediated by 1,2-DHX in macrophages, the 
expression of cytokines, namely interleukin - 1β (IL-1β) and tumor necrosis factor - α  
(TNF- α) (characteristic of a M1 phenotype) and tumor grow factor - β1 (TGF-β1) and IL-
10 (characteristic of a M2-like phenotype) was evaluated. 
Macrophages are dynamic and heterogeneous cells mainly due to their capacity to 
respond to stimulus. According to the microenvironment they may be polarized into a 
spectrum of phenotypes ranging from the pro-inflammatory M1 (classic) to the 
immunossupressive M2 (alternative) (Allavena et al. 2008; Biswas et al. 2013). Several 
evidences indicate that macrophages phenotypes can change during tumor progression 
(Zaynagetdinov et al. 2011). M1 activation may induce chronic inflammation, a factor that 
could predispose to tumor initiation (Greten et al. 2004; Pikarsky et al. 2004). However, in 
early stages of tumor progression, TAMs adopt a M1-like phenotype that contributes to 
tumor immunity. M2 phenotype is mainly expressed in established tumors and induce 
immunosuppressive, angiogenic and metastatic effects (Mantovani et al. 2004; Sica et al. 
2006; Gordon and Mantovani 2011; Zaynagetdinov et al. 2011; Liao et al. 2014). 
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1,2-DHX suppress the expression of IL-1β to concentrations similar to basal and 
stimulated TNF-α expression. It also inhibited IL-10 production and stimulated TGF-β1 
expression but only at concentration above GI50 (100 µM), while any alteration was 
detected at lower concentration. 
IL-1β, a pro-inflammatory cytokine mainly produced by monocytes and macrophages is 
an example of the pleiotropism of immune system. In melanoma its expression was 
associated to tumor progression and promotion of lung metastases from melanoma 
(Giavazzi et al. 1990; Meyer et al. 2011). Therefore, IL-1β has been associated with all 
steps of malignancy (carcinogenesis, progression, invasion and metastasis) and may 
even be expressed by the tumor cells (Apte and Voronov 2008). In contrast, it induces an 
immune response against malignant cells associated to the M1 macrophages phenotype 
(Fairweather and Cihakova 2009). 
TNF-α stimulation predicts a favorable outcome in melanoma treatment since several 
reports associated the use of TNF inhibitors as a factor that appear to increase the risk of 
skin cancer, including melanoma (Mariette et al. 2011; Kouklakis et al. 2013). TNF-α 
expression by THP-1 cells at basal and LPS-stimulated level was significantly lower when 
compared to 1,2-DHX treated cells. 
IL-10 and TGF-β1 are anti-inflammatory cytokine involved in carcinogenisis process. In 
melanoma, IL-10 was associated with metastatic formation (García-Hernández et al. 
2002; Itakura et al. 2011) and TGF-β1 are highly expressed and increase in parallel with 
tumor progression (Krasagakis et al. 1998; Javelaud et al. 2008). In spite of the 
differences observed, the antitumor effect of 1,2-DHX conditioned macrophages medium 
was not due neither to IL-10 nor TGF-β1 expression, since for treatment with 50 µM of 
1,2-DHX no significantly differences were observed for the expression of these cytokines 
by THP-1 macrophages. 
Production of nitric oxide (NO) by macrophages in tumors has controversial funtions. It 
was reported that below a critical concentration of NO, it causes DNA mutations (Wink et 
al. 1998), inhibits apoptosis (Choi et al. 2002), promotes angiogenesis (Ziche and 
Morbidelli 2000), limits immune response against cancer (Wink et al. 1991) and promotes 
metastasis (Lala and Orucevic 1998). When it exceeds the critical concentration, NO 
induce apoptosis and suppress the growth of the tumor (Choudhari et al. 2013). NO has 
been reported as cytotoxic in melanoma and many other tumors, but simultaneously it 
modulates many pro-tumor pathways including resistance to apoptosis, cell cycle 
progression, angiogenesis invasion, and metastasis (Ying and Hofseth 2007; Choudhari 
et al. 2013). In order to clarify this relation and better understand the mechanism mediated 
by 1,2-DHX in macrophages, production of NO by macrophages was evaluated. 
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In NO production assay, RAW 264.7 was used instead of THP-1 human macrophages 
cell line since this was referred as an appropriet model to study iNOS system (Dirsch et al. 
1998; Shih et al. 2010). Human macrophages in vitro produce low quantitie of NO in 
response to stimuli (Thomassen and Kavuru 2001). However either in vitro murine cells as 
in vivo human macrophages express great quantities of NO in inflammatory conditions 
(Ochoa et al. 1991; Dirsch et al. 1998) 
1,2-DHX is a potent inhibitor of NO production by LPS-stimulated RAW 264.7 murine 
macrophages cell line (IC50 = 22.0 ± 0.9 µM). This effect was not due to cell death or to 
NO scavenging, thus it was proved that interference was at the level of NO production. 
In stimulated macrophages, NO is produced by the inducible form of NO synthetase 
(iNOS or NOS2) from L-arginine and molecular oxygen (Gross and Wolin 1995; Aramaki 
2000). NOS2 gene regulation, as the majority of genes may occur at transcriptional and 
post-transcriptional level (Nathan and Xie 1994; Bogdan et al. 2000; Brunet 2001).  
With the purpose of evaluate the time point when the compound interfere with the 
enzyme to inhibit NO production, xanthone was added at different hours: 0h 
(simultaneously), 6h and 14h after RAW 264.7 macrophages stimulation with LPS. 
Although, 1,2-DHX added simultaneously has potent inhibition; when it was added 6h 
after stimulation the effect decreased significantly (p < 0.001) and when added after 14h, 
the effect was nule. This finds leads us to conclude that the compound may exerts their 
action by interfering with iNOS expression, once this enzyme is transcripted within 2-4 
hours and translated within six hours after LPS-stimulation in macrophages (Xie et al. 
1994). L-NAME (inhibitor of iNOS activity) (McCall et al. 1991), and Dexamethasone, 
inhibitor of iNOS expression (Korhonen et al. 2002) was used as positive controls and the 
obtained results was in accordance with the mechanism proposed to these inhibitors by 
our technique. 
Inhibition of iNOS indicated an anti-inflamatory potential of 1,2-DHX. However, 
inflammation and NO production has controversial effects in cancer. NO has been 
reported as cytotoxic in melanoma and many other tumors, but simultaneously it 
modulates many pro-tumor pathways including resistance to apoptosis, cell cycle 
progression, angiogenesis, invasion and metastasis (Ying and Hofseth 2007; Choudhari 
et al. 2013). 
The underling mechanism of inhibition of iNOS expression by 1,2-DHX may be 
explained by the stimulation of TGF-β1. This cytokine has been reported as a destabilizer 
of iNOS mRNA avoiding gene translation and inhibiting NO production. Involvement of 
NF-κB pathway may also be involved since it contributes to iNOS synthesis and 
upregulate IL-1β level and 1,2-DHX treated THP-1 macrophages expressed either lower 
IL-1β and NO levels comparatively to control cells. This finds leads us to hypothesize the 
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interference of the xanthone with NF-κB pathway. More studies must be performed in 
order to corroborate this supposition. 
The set of all data find in this study allowed to infer a potential of 1,2-DHX in melanoma 
treatment, due to its cytotoxic activity through direct inhibition of cell growth and by 
modulation of macrophages immune microenvironment. Characteristics of 1,2-DHX in 
melanoma are even more important taking in account the lack of appropriated therapeutic 
alternatives in this tumor. However, further studies are needed to attest this relation in 
vivo. 
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The present study comprised the evaluation of antitumor and effect of two different 
xanthones: alpha-mangostin obtained from mangosteen and 1,2-dihydroxyxanthone 
obtained from synthesis, and their involvement in several parameters of immune system, 
concerning their anticancer activity. Interference of α-MG was tested in cells of innate and 
adaptive immune system, while 1,2-DHX was only evaluated in macrophages due to 
recent studies in lymphocytes performed by our group. 
The main conclusions from the results of this study are as followed: 
 
Antitumor activity of compounds: 
 α-MG and 1,2-DHX showed to be good inhibitors of A375-C5 melanoma cell line 
growth. However, the potency of the cytotoxic effect of α-MG was significantly 
higher than that of 1,2DHX. 
 
Antitumor activity of macrophages conditioned culture medium: 
 1,2-DHX interfered with the immune macrophages-dependent microenvironment of 
A375-C5 melanoma cells; 
 For α-MG this effect was not clearly observed, probably due to the doses tested;  
 
Inhibition of NO production: 
 Expression of NO by RAW 26.7 macrophages was suppressed after treatment with 
α-MG and 1,2-DHX and, once again, a more significant inhibition was obtained for 
α-MG. 
 Inhibition of NO production by these compounds is probably a consequence of 
inhibition of NOS2 gene expression, occurring just after stimulation.  
  
Interference of cytokine expressed by THP-1 macrophages: 
 α-MG and 1,2-DHX decreased the expression of IL-1β, a pro-inflammatory 
cytokine associated to carcinogenesis, progression, invasion and metastases, and 
either as  mediator of immunosurveillance. 
 α-MG also inhibit the anti-inflammatory cytokine ,TGF-β1, which may compromise 
the tumor immune scape and it could allow an immune response against tumor. 
 At concentration above GI50, 1,2-DHX suppressed IL-10 and stimulated TGF-β1, 
however it cannot be associated to antitumor effect of supernatants of treated 
macrophages since it was not verified at the concentration must closer GI50. 
 Stimulation of TGF-β1 by 1,2-DHX could explain the inhibitory effect against iNOS 
by this compound. This cytokine has been reported as a destabilizer of iNOS 
mRNA avoiding gene translation and inhibiting NO production. 
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 The inhibition of IL-1β mediated by α-MG may ilucidate the underlaing mechanism 
of inhibition of NO production since IL-1β stimulate NF-κB pathway that, in turn, 
activate the expression of iNOS enzyme. 
 IL-10 and TNF-α concentrations did not alter in macrophages treated with α-MG 
comparatively to non-treated macrophages; while only TNF-α concentration 
remains stable in 1,2-DHX treated macrophages. 
 
Antiproliferative activity against human lymphocytes: 
 α-MG strongly inhibit prolipheration of human T lymphocytes from peripheral 
blood. 
 α-MG also reduced the expression of IL-10 and TNF-α to basal levels in these 
cells, but only at concentration much higher than IC50 which indicates a 
interference in cytokines proliferation without affect cytokines expression. 
 
 
In summary, this dissertation allows to infer the potential of alpha-mangostin and 1,2-
dihydroxyxanthone xanthones in melanoma treatment due to their cytotoxic activity and 
suggestive effect in cancer immunotherapy. 
Although, further studies are needed to attest and explain the mechanism of action of 
xanthones against melanoma. 
 
